The Effects of Environmental Stressors and Stressor Interactions on the Evolutionary Dynamics of Bacterial Population and Gene Epistasis by Kang, Manzhu
UCLA
UCLA Electronic Theses and Dissertations
Title
The Effects of Environmental Stressors and Stressor Interactions on the Evolutionary 
Dynamics of Bacterial Population and Gene Epistasis
Permalink
https://escholarship.org/uc/item/2fv5c2m4
Author
Kang, Manzhu
Publication Date
2019
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
 UNIVERSITY OF CALIFORNIA 
Los Angeles 
 
 
 
The Effects of Environmental Stressors and Stressor Interactions on the Evolutionary Dynamics 
of Bacterial Populations and Gene Epistasis 
 
 
A dissertation submitted in partial satisfaction of the requirements for the degree  
Doctor of Philosophy in Biology 
 
by 
 
Manzhu Kang 
 
 
 
 
2019 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by 
Manzhu Kang 
2019
 ii 
 
ABSTRACT OF THE DISSERTATION 
 
The Effects of Environmental Stressors and Stressor Interactions on the Evolutionary Dynamics 
of Bacterial Population and Gene Epistasis 
 
by 
Manzhu Kang 
Doctor of Philosophy in Biology 
University of California, Los Angeles, 2019 
Professor Pamela J Yeh, Chair 
 
Environmental stressors come in many different forms and affect every level of ecological 
organization. In a natural environment, organisms experience mixtures of stressors at various doses 
or strengths of exposure that could be constantly changing, both temporally and spatially. Complex 
environmental regimes and interactions among multiple stressors can have a profound effect on 
both the short-term fitness of organisms and their long-term evolutionary dynamics. This 
dissertation uses a bacterium-drug system to study drug-drug, drug-temperature, and gene-gene 
interactions. The first question we ask is how bacteria evolve to combat new stressors. Through an 
interaction network clustering approach followed by transcriptomic analysis, we show that 
Escherichia coli may have co-opted its cellular response to temperature stress for antibiotic stress 
because these stressors share similar physiological effects.  We also found that antibiotic stress 
modifies the thermal response of E. coli by altering both its optimal growth temperature and 
 iii 
temperature breadth. Next, we ask how we can identify and quantify dose-dependent drug 
interactions, including interactions among more than two components, i.e., higher-order 
interactions. To do this, we introduce a novel visual representation termed interaction landscape 
to directly map local dose-dependent interactions and the transitions between different interaction 
classes. Finally, we ask how gene-gene interactions change in fluctuating environments. We 
showed that changes in the type and magnitude of environmental fluctuations could affect fitness 
due to the differences in epistatic interactions of mutations. We quantify structural features of 
fitness landscapes by calculating the ruggedness across broad concentration gradients of various 
antibiotics. We show that fluctuating environments frequently lead to epistasis sign switches (from 
negative to positive or vice versa) on the pairwise level, as a potential mechanism to either promote 
specialization or maintain genetic variation. Overall, this dissertation combines experimental, 
mathematical, and computational biology to identify and understand the structures and patterns of 
interactions at different scales and their effects on the fitness and eco-evolutionary dynamics of 
bacterial populations. 
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CHAPTER 1 
Introduction 
 
Environmental traits can be critical drivers in many ecological and evolutionary processes 
such as niche differentiation [1, 2], biodiversity [3-5], adaptation [2, 6], and extinction [7, 8]. 
Within a specific environmental condition, a stressor can be defined as any factor that reduces the 
fitness of an organism [9]. Organisms likely experience a myriad of stressors simultaneously. 
Sensing, responding, and adapting to various stressors and mixtures of stressors present a great 
evolutionary challenge [10, 11].  
Microorganisms inhabit almost every environment on Earth [12]. For example, 
cyanobacteria can survive in extreme temperatures from Antarctic ice to continental hot springs 
[13]. Most foodborne pathogens such as Escherichia coli can persist in diverse environments both 
inside and outside of the host [14]. These microbes are constantly challenged by a combination of 
various stressors, such as antibiotics, changes in temperature, varying pH, or starvation [14]. From 
the public health standpoint, bacteria that evolve antibiotic resistance have caused a widespread 
public health care crisis.  Each year in the United States alone, antibiotic resistance is related to 
roughly 2 million infections and 23,000 deaths [15]. For ecologists and microbiologists, 
microorganisms can be ideal systems to examine diversity and function. For example, soil 
microbes are vital for regulating productivity and nutrient cycling [16, 17], and the gut microbiota 
is now recognized as a crucial factor for the health and even behavior of the host [18-20].  
The laboratory strain of E. coli is one of the most studied model organisms widely used in 
molecular biology and microbiology studies [21]. It is also the subject of an ongoing study in 
experimental evolution led by Richard Lenski since 1988 [22]. There are many advantages to using 
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bacterial populations to study evolution [23]. They are clonal organisms that can be grown in the 
laboratory with highly controlled and replicable experiments. Their small genome sizes allow easy 
and low cost for genetic manipulation and genomic analysis. The short replication time and small 
culture volume allow the researchers to maximize the throughput with the help of automated 
platforms. Taken together, studies of microorganisms have proven to be highly applicable and 
valuable in answering some of the most fundamental questions in ecology and evolutionary 
biology [23-28].   
This dissertation exploits these advantages, using a bacterium-drug system to understand 
how the external environment, especially with the presence of various types (different drugs) and 
intensities (different concentrations of drugs) of stressors, affects the fitness and eco-evolutionary 
dynamics of bacterial populations. Chapter 2 focuses on revealing the potential evolutionary 
strategy of E. coli to combat novel stressors based on the interaction properties between antibiotics 
and stressful temperatures. Chapter 3 examines the overall physiological effect of combined 
exposure to antibiotic and temperature stress by quantifying the thermal response and emphasizes 
the important implication for a general understanding of how ecological systems adapt to 
environmental challenges on shorter timescales. Chapter 4 aims to understand dose-dependent 
interactions, focusing on the prevalence, strength, and structure of interactions based on the 
intensity of the drug dosage. Finally, chapter 5 uses fitness landscapes to show how the magnitude 
or severity of environmental change affects phenotypic fitness due to their effect on gene-gene 
interaction or epistasis.  
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 CHAPTER 2  
Stressor Interaction Networks Suggest Antibiotic Resistance Coopted from Stress Response 
to Temperature 
 
2.1 Introduction  
 
Organisms encounter and respond to myriad stressors [29, 30]. Stresses to bacteria can 
come in many different forms, such as use of antibiotics [31, 32], changes in temperature [33], 
variations in salt concentration or pH [34], or a lack of nutrients [35]. Cellular responses to these 
stressors vary but can range from specific subcellular mechanisms such as efflux pumps that pump 
out toxic compounds [36, 37] and outer membrane porins that regulate osmolarity [38] to more 
global modulation that includes dormancy or quiescence under nutrient limitation [39].  
Temperature is one of the stressors that living organisms have needed to contend with since 
life first evolved [40-43]. Indeed, phylogenetic evidence based on ribosomal RNA sequences 
places the emergence of hyperthermophiles near the root of the tree of life [44, 45], so sensing, 
responding, and adapting to temperature must constitute some of the oldest adaptations in nature. 
The heat-shock response machinery, which is a mechanism for cells to combat the noxious effects 
of high temperatures, is present across all domains of life and is highly conserved [46-49]. In 
contrast, the first antibiotics are thought to have arisen more recently in evolutionary history, 
between 2 billion and 40 million years ago [50]. Consequently, it seems likely that adaptive 
responses to variations in environmental temperature evolved before responses to antibiotics. It 
seems possible that some of the mechanisms that confer resistance to variations in temperature 
have been co-opted to resist antibiotic stress as well, especially since temperature and drugs impact 
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many of the same cellular components. In addition to functional overlap, there are compelling 
reasons for cells to evolve a relatively small suite of stress responses to multiple types of stressors. 
Developing a novel stress response requires investment in terms of genetic material (i.e., 
information), protein production, time to evolve, and energy to support simultaneous responses. 
Thus, it is highly inefficient therefore unlikely for a cell or organism to evolve an independent 
response for every single stressor it encounters.  
For example, in response to two different types of stressors—drugs and heavy metal—
many Gram-negative bacteria, such as Pseudomonas aeruginosa, evolved an efflux pump that 
actively pumps out all toxic molecules [51]. Another example of a general response machinery to 
different stressors in bacteria is the alternative sigma factor S, a transcription factor that regulates 
the expression of more than 70 genes that confer resistance against stresses as diverse as 
temperature change, starvation, pH, and DNA damage [52-54]. Together, these studies suggest 
bacteria have similar responses to multiple types of stress that harm the same cellular components 
(e.g., DNA, protein, cell membrane, or cell wall). 
It is natural to ask which response mechanisms evolved first, whether these original 
responses were co-opted to respond to other stressors, and how much overlap exists among how 
stressors affect bacteria. For instance, both temperature and antibiotics can harm similar cellular 
functions: high temperatures and antibiotics (e.g., macrolides and aminoglycosides) both affect 
protein synthesis and folding [55, 56]. Heat shock proteins can be induced by some antibiotics 
[57], and that resistance to antibiotics can be temperature dependent [58]. Furthermore, heat-
adapted Escherichia coli could require resistance to rifampicin, despite the drug being absent 
during the selection process [59]. Additionally, overexpression of heat-shock proteins increases 
short-term survival of bacteria exposed to aminoglycosides [60]. Other stress responses, such as 
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those for nutrient starvation and oxidative stress, have also been linked to the emergence of 
antibiotic resistance [61].  
Typically, this overlap between cellular responses to stress has been studied by isolating 
subcellular parts and attempting to piece together the information involved to understand stress 
responses at a whole-cell level. Despite these intriguing, isolated subcellular studies, we are 
unaware of any systematic, comprehensive study of these overlaps and co-opting. The lack of such 
a study is partly because obtaining direct data is extremely challenging in terms of the cellular 
pathways that need to be dissected, the evolutionary time scales that must be used, and the differing 
selection pressures that need to be manipulated and observed.  
Here, we take a reverse and complementary approach: by studying the effect of 
perturbations on the whole system, we gain more insights into the mechanisms of its specific parts. 
It is now feasible to accomplish this because of recent progress on high-throughput data collection 
and on methods that reveal the mechanisms of antibiotics using network clustering [62, 63]. For 
these clustering methods, interactions are characterized based on growth assays of bacteria 
exposed to antibiotic combinations. Interaction networks can then be constructed by collecting the 
full factorial of interactions among several antibiotics. Clustering this network according to 
interaction profiles (a procedure called monochromatic clustering) yields groups of drugs with the 
same mechanisms of action [63]. This relationship between mechanism and interactions likely 
arises because the mechanism of action corresponds to functional impacts on the cell that map with 
high fidelity to the effective interactions among the antibiotics. The interaction profile of a drug 
can thus reveal its effect in the cell and its mechanism of action. A great benefit of this approach 
is that it does not require as much time or resources as molecular studies. In these studies, 
interactions between drugs are typically characterized in one of three ways: additivity (drugs have 
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independent effects on growth), synergy (combined effect of the drugs is greater than expected 
based on single-drug effects), or antagonism (combined effect is smaller than expected) [64]. We 
will follow the same nomenclature in this paper to describe interactions between temperatures and 
drugs. 
Here we generalize and extend the ideas of monochromatic clustering. We develop a 
clustering method for stressor interaction networks (SINs) to categorize non-drug stressors that 
affect bacterial growth, and to further reveal information about the shared effects of temperature 
and antibiotics on the cell.  
Here, we derive for the first time how to accomplish this for the case of non-optimal or 
extreme temperatures. We collect comprehensive data on bacterial growth in the presence of each 
stressor separately, and when pairs of stressors are present simultaneously. We analyze these data 
to identify groups of antibiotics that have similar physiological effects to low and high temperature 
stress. This physiological similarity is inferred by grouping stressors that interact similarly with 
other stressors, as revealed through the SIN clustering analysis, and grounded in the original 
intuition of monochromatic clustering. In this way, we systematically analyze overlap between 
stress responses to temperature and antibiotics to assess the extent that cellular responses to drugs 
co-opt and mimic the responses to temperature, an ancient stressor. More specifically, we quantify 
to what extent the physiological effects of temperature in the cell are shared across a wide range 
of temperatures or if there is more nuanced variation. Finally, we use these results to identify 
common functional aspects of stressors that we use to help develop a classification system for 
stress responses.  
Intriguingly, our results are consistent with low and high temperature stress responses 
having been co-opted through evolution to combat multiple classes of antibiotics.  Because the 
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monochromatic clustering methodology depends only on the existence of an interaction network, 
it seems possible to apply a similar methodology to broader types of interactions among multiple 
types of stressors.  
 
2.2 Materials and Methods 
 
Bacterial strain 
The study primarily used BW25113, a derivative of the F-, λ-, E. coli K-12 strain BD792 
(CGSC6159) [65]. For each bacterial strain, a single colony was inoculated into 2 mL of LB media 
(10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) and grown overnight followed by 
resuspension in 25% glycerol, then aliquoted into 50μL and frozen at -80°C. Cultures used for 
daily experiments were started by adding 20μL of thawed aliquots into 2mL of LB media. The 
culture was incubated at 37°C until it reached exponential growth phase and diluted to maintain 
104 cells per experimental condition.  
Compounds and Materials 
A total of 12 antibiotics were included in the study as representatives of all major drug classes. 
Gentamycin (GEN), levofloxacin (LVX), tetracycline (TET), tobramycin (TOB), erythromycin 
(ERY), ampicillin (AMP), clindamycin (CLI), streptomycin (STR), nitrofurantoin (NTR), 
cefoxitin (FOX), and trimethoprim (TMP), all from Sigma (St Louis, Mo); and ciprofloxacin (CPR) 
from MP Biomedicals (Santa Ana, Ca). Stock solution at 20 mg/mL of each antibiotic was stored 
in 50μL aliquot at −20°C and each aliquot was only frozen and thawed once to preserve potency.  
2.2.3 Growth experiment 
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Drug concentrations were selected to partially inhibit bacterial growth (10% to 50% inhibition) 
that were first determined by a twelve step concentration series of 2-fold at each step in 96-well 
plates (Costar). A 5 ml stock solution of each drug in LB media was made at 10-fold of their 
respective concentrations (Table 2-1). For drug pair experiments, 10μL of each component drug 
was mixed into 96-well plates followed by the addition of 80μL cell inoculum; while 10μL of LB 
media was added in replacement of a second drug for single drug experiments. Replicate plates 
were prepared from the same antibiotic stock solution to minimize variation and incubated at 300 
rpm in parallel at various temperatures (E. coli: 22°C, 25°C, 30°C, 37°C, 41°C, 44°C, 46°C). 
OD600 measurements for cell density were taken after 4-hour, 8-hour, 12-hour and 24-hour growth 
for E. coli.  To examine the drug interaction clustering of E. coli in a different external environment, 
we used LB media without salt. The media was prepared with 10 g/L tryptone, 5 g/L yeast extract 
in every liter.  
 
Table 2-1 Antibiotics and doses used for the antibiotic-temperature SIN clustering experiments 
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Gene expression profile 
We measured expression of about 2000 genes in E.coli using the promoter library of transcriptional 
fusion of gfp to each promoters [66]. Strains were maintained in 15% glycerol at -80°C before 
inoculating and grown overnight in LB medium with 25 μg/mL of kanamycin in 384 well plates. 
Cultures were then transferred and pinned into 50 μL of LB medium per well, followed by a 4-
hour incubation at 37°C to allow growth up to exponential phase. To measure differential 
expression at high temperature, cultures were moved to 44°C where optical density of 595 nm and 
GFP fluorescence (excitation, 480 nm; emission, 535 nm) were measured every 2 hours for 24 
hours using a programmable robotic system (Thermo Cytomat). For expression profile with 
antibiotic treatments, cultures were pinned into 30 μL of LB medium before 4-hour incubation, 
and another 30 μL of LB medium with 2X concentration of antibiotics (STR at 4 μg/mL and TET 
at 1 μg/mL) were added into the plates. Controls were carried out at 37°C without temperature 
shift or addition of antibiotics. Antibiotics and control conditions were measured using the same 
robotic system and time frame.  
Drug sensitivity profile for heat adapted strains 
We profiled antibiotics sensitivity for 10 high temperature adapted lines collected and described 
by Rodriguez-Verdugo et al. [67].  In addition, we compared their sensitivity profiles with the 
ancestral strain of E. coli B (genotype REL1206). IC 50 for 12 drugs was determined by a 11-step 
concentration series of 2-fold in 3 replicates, method described in previous sections under Growth 
experiment.  
Relative growth and interactions 
The relative growth under stressor 𝑥 (presence of a drug or a non-optimal temperature) is defined 
as 𝑤𝑥 =
𝑔𝑥
𝑔𝜑
, where 𝑔𝑥  is the growth of the bacterial culture under stressor 𝑥 and 𝑔𝜑 is the growth 
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of the culture at reference state 𝜑 —the culture at its optimal temperature for growth in the absence 
of antibiotics. Under the Bliss Independence criterion [64], an interaction is additive if 𝑤𝑥𝑦 =
𝑤𝑥𝑤𝑦 , where 𝑤𝑥𝑦 =
𝑔𝑥𝑦
𝑔𝜑
 is the relative growth when stressors 𝑥  and 𝑦  are both present. The 
deviation from additivity is defined as 𝜀𝑥𝑦 = 𝑤𝑥𝑦 − 𝑤𝑥𝑤𝑦 . When this measure is significantly 
nonzero, it signifies an interaction exists. The sign of this measure determines the interaction type 
(𝜀𝑥𝑦 < 0 corresponds to synergy and 𝜀𝑥𝑦 > 0 to antagonism). The raw 𝜀𝑥𝑦 is then rescaled by 
appropriate reference values (as in [63]) to yield a rescaled measure, 𝜀?̃?𝑦. Its magnitude can be 
interpreted as the strength of interaction.  
Statistics 
With the experimental procedure detailed above, four measurements of the OD600 were taken at 
every time point, each one corresponding to a different growth curve, for each stressor and all 
possible pairwise combinations. The OD (optical density) values were used as a proxy that is  
proportional to the absolute growth (𝑔𝑥 , 𝑔𝑦 , 𝑔𝑥𝑦 , 𝑔𝜑). We chose the point estimate 𝑔𝑥  to be the 
sample mean of the four measurements of absolute growth under condition 𝑥. The point estimate 
for each relative growth was taken to be ?̂?𝑥 =
?̂?𝑥
?̂?𝜑
 and the point estimate for the interaction 𝜀̃̂𝑥𝑦 =
𝜀̃(?̂?𝑥 , ?̂?𝑦 , ?̂?𝑥𝑦) . We followed a parametric bootstrap approach for constructing a confidence 
interval for the interaction, with the assumption that the absolute growth (i.e., OD) measurements 
under each condition follow a log-normal distribution. The maximum likelihood estimators (which 
correspond to the sample mean and variance of the logarithm of the observations) were used to 
estimate the parameters of the underlying distribution for the absolute growth under each condition. 
We then took 20000 parametric bootstrap samples of 𝑛 = 4 observations from the log-normal 
distribution with the estimated parameters. The mean of each one of these samples was used to 
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construct a bootstrap sample for the mean relative growth values (?̂?𝑥
(𝑖), ?̂?𝑦
(𝑖), ?̂?𝑥𝑦
(𝑖)), and the 
interactions 𝜀̃̂𝑥𝑦
(𝑖)
= 𝜀̃(?̂?𝑥
(𝑖), ?̂?𝑦
(𝑖), ?̂?𝑥𝑦
(𝑖)), where 𝑖 = 1, … ,20000. A 95% confidence interval 
for 𝜀?̃?𝑦 was constructed by taking the 2.5 and 97.5 percentiles of its bootstrap sample.  
Network of antibiotic and temperature effects  
We construct an interaction network where nodes represent the stressors (i.e., drugs or 
temperatures), and colored edges represent non-additive interactions, with the edge color 
corresponding to interaction type (red for synergy and green for antagonism). In general, exact 
additivity (𝜀?̃?𝑦 = 0) is rare, but there is nevertheless an important qualitative distinction between 
approximate additivity (i.e., |𝜀?̃?𝑦| ≤ 𝜀?̃?𝑒𝑓), where 𝜀?̃?𝑒𝑓 is a threshold below which an interaction is 
considered approximately additive) and strong synergistic and antagonistic interactions. Since the 
observed interactions are subject to measurement error and population variability, we only assign 
edges for which the confidence interval (𝜀2̃.5, 𝜀9̃7.5) for 𝜀?̃?𝑦 excludes the critical value 𝜀?̃?𝑒𝑓. We 
thus define the discretized interaction (i.e., color) of an edge to be 
𝑐(𝜀2̃.5, 𝜀9̃7.5) = {
1 (green) 𝜀2̃.5 > 𝜀?̃?𝑒𝑓
−1 (red) 𝜀9̃7.5 < 𝜀?̃?𝑒𝑓
0 (no edge) otherwise
 
The higher this critical value, the stronger an interaction needs to be to be assigned as an edge in 
the network. Thus, with values that are too low, weak effects can be assigned as interactions, and 
with values that are too high, there may not be enough assigned interactions (i.e., edges) in the 
network for the clustering algorithm to be effective. We chose 𝜀?̃?𝑒𝑓 = 0.2 because empirically this 
yielded a good compromise between the two. With this definition, the discretized nonzero value 
of 𝑐 corresponds to a statistically significant interaction, with 𝑐 = −1 (red edges) corresponding 
to synergy and 𝑐 = 1 (green edges) to antagonism. When 𝑐 = 0, we either cannot reject additivity 
or there is missing data.  
 12 
Monochromatic clustering 
The stressors in the interaction network were clustered into monochromatic classes using a newly 
developed modification of the Prism 2 algorithm [63]. The algorithm was implemented in the 
Python programming language. Each node starts in a different cluster, and at each iteration of the 
algorithm, the pair of clusters (𝑋, 𝑌)  that minimizes the penalty 
𝐹(𝑋, 𝑌) = 𝑘𝐷𝐷(𝑋, 𝑌) + 𝑘𝑆(∆𝑆(𝑋, 𝑌) + 𝛼(1 − 𝑝𝑋𝑌)) 
is merged. This procedure is repeated until a single cluster remains, containing all nodes in the 
network. The first two terms in 𝐹(𝑋, 𝑌) are identical as in the previous version of the algorithm 
[63]. Their function is to penalize merging clusters that have dissimilar interactions to each other 
(represented by the weighted distance term: 𝐷(𝑋, 𝑌) ) and that result in non-monochromatic 
clusters (through the entropy term: ∆𝑆(𝑋, 𝑌)), respectively.  
A new aspect of the algorithm, which is not present in previous versions, is the term 𝛼(1 − 𝑝𝑋𝑌), 
where, 𝑝𝑋𝑌 is the proportion of shared edges between clusters 𝑋 and 𝑌, and 𝛼 is an arbitrary tuning 
constant. The purpose of this term is to penalize the entropy term so that joining clusters with more 
shared interactions is favored with respect to clusters with no or few shared edges. Without this 
term, it is always possible to form monochromatic clusters by simply merging clusters with 
member nodes that have no or few shared edges. However, these clusters need not have similar 
overall interactions, and thus lack any physiological information. Our modified algorithm avoids 
this problem and outcome. 
Note that in this formulation we also chose to write ∆𝑆(𝑋, 𝑌) with an opposite sign as in [63], to 
be consistent with the usual convention that positive values mean increases and negative values 
mean decreases. Within the penalty 𝐹(𝑋, 𝑌), each term is multiplied by a constant that affects the 
relative weight of each term. We chose the weights 𝑘𝐷 = 1 and 𝑘𝑆 = 0.1 as in [63]. The tuning 
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constant, 𝛼 = 0.1, is new to this work, and was chosen to be of roughly the same order of 
magnitude, but smaller than the change in entropy ∆𝑆(𝑋, 𝑌) ∈ [0,1]. This choice of 𝛼  gives 
clusters that better separate antibiotics according to mechanism of action for networks with a small 
number of edges. Another difference with respect to the previous algorithm is that we use the mean 
distance between the antibiotics (known as average linkage) as the metric for distance between 
clusters 𝐷(𝑋, 𝑌). This choice is less sensitive to outliers than the previous choice of the minimum 
distance.  
 
2.3 Results 
 
Clustering of an antibiotic and temperature interaction network reveals overlap in their 
physiological effects 
To find groups of stressors (i.e., antibiotics and/or temperatures) that have similar effects 
on E. coli physiology, we first evaluate the interactions—synergy, additivity, or antagonism—
between each pair of antibiotics, and between each antibiotic within a range of growth 
temperatures (22°C, 25°C, 30°C, 37°C, 44°C, 46°C) (Figure 2-1a, b). The maximum growth in the 
absence of antibiotic was observed at 41°C: this optimum growth temperature was chosen as the 
unstressed reference state for evaluating the relative growth in the presence of each stressor. We 
evaluate the interactions based on the 24-hour growth of E. coli after exposure to the corresponding 
stressors. We then construct a stressor interaction network (SIN) (Figure 2-1c) where nodes 
represent the stressors and colored edges represent interaction type (discretized based on a 
hypothesis test, see Figure 2-1c and Methods 2.2). The resulting network is clustered to find 
 14 
monochromatically interacting groups, which correspond to similar interaction profiles, using our 
modified Prism 2 algorithm (Figure 2-1d, see Methods 2.2 for details of the algorithm). 
 
Figure 2-1 Schematic illustration of the approach taken in this work. a Growth is measured in the following 
conditions: reference growth gφ at the optimal temperature (Topt = 41 °C) in the absence of drug, gx at 
optimal temperature with drug, gy at experimental temperature Texp, but no drug, and gxy at non-optimal 
temperature with drug. b The growth of each experimental condition is converted to proportions wx, wy, 
wxy by dividing by the reference growth. The difference between wxy (observed growth) and the product 
of wx and wy (expected growth under independence) is then used to classify the interaction between drugs 
and temperatures into three cases: synergistic (red line), additive (white or not shown), and antagonistic 
(green line), c which can be represented as an interaction network. d Drugs and temperatures can then be 
clustered into a functional class based on the mono- chromaticity of interactions with a different class. This 
example shows a drug-temperature interaction, but drug–drug interactions are obtained similarly, by 
replacing the growth with no drug at Texp with the growth under a second drug at Topt.  
 
 
  Consistent with overlap in the mechanism of action of specific drugs and the physiological 
effect of non-optimal temperatures, we find that the evaluated temperatures cluster with antibiotics 
in the following three groups (Figure 2-2): (1) All temperatures lower than the temperature for 
peak growth cluster together, along with the fluoroquinolones (LVX, CPR), which are DNA gyrase 
inhibitors, and with the 30S protein synthesis inhibitor tetracycline (TET). (2) The temperature 
44°C clusters with the DNA-damaging drug nitrofurantoin (NTR) and with trimethoprim (TMP), 
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an inhibitor of the folic acid biosynthesis pathway that is responsible for generating an essential 
DNA precursor. (3) The highest evaluated temperature, 46°C, clusters with the aminoglycosides 
(GEN, STR, TOB), antibiotics that affect protein translation proofreading [68]. We thus conclude 
that monochromatic clustering successfully separated the antibiotics according to their mechanism 
of action and/or grouped with temperatures that have similar physiological effects.  
 
Figure 2-2 Monochromatic clustering of the interaction network. a Unclustered interaction network. The 
nodes that correspond to drugs are color-coded by their mechanism of action (Table 1), and the nodes that 
correspond to temperatures are colored in a gradient from blue (low) to red (high). The edges correspond 
to discretized interaction type: synergy (red), antagonism (green), additive or unknown (no edge). b 
Network clustered into monochromatic classes by the modified Prism2 algorithm.  
 
 
To evaluate the robustness of our clustering results, we also measure interactions in a 
different condition: LB medium with no salt (Figure 2-3). As before, we find that high 
temperatures cluster with aminoglycosides (GEN, STR, TOB) and TMP, but now they cluster in a 
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single group. Low temperatures cluster in a single group with CLI, a 50S protein synthesis inhibitor, 
instead of TET, LVX, CPR. 
Figure 2-3 Interactions and clustering under no salt conditions. The interaction effect (ε ̃) values are color 
coded in a gradient, from synergy (red) to additive (grey) and antagonism (green). (a) Matrix heatmap of 
the mean interaction effects. Antibiotics with the same mechanism of action show similar interaction 
patterns. (b) Matrix heatmap of the discretized interaction types used for constructing the edges of the 
interaction network. (c) Network clustered into monochromatic classes by the modified Prism2 algorithm.  
 
Patterns in antibiotic and temperature interactions 
We find that the distribution of the interactions between all pairs of stressors at 24-hour growth is 
trimodal (Figure 2-4a), with peaks that correspond to synergy (𝜀?̃?𝑦 ≈ −1), additivity (𝜀?̃?𝑦 ≈ 0) 
and antagonism ( 𝜀?̃?𝑦 ≈ 1 ), similar to previous work [63]. Ampicillin (AMP) and the 
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aminoglycosides (GEN, STR, TOB) are mostly antagonistic with temperatures lower than the 
optimum (41°C), and synergistic or additive with higher temperatures (Figure 2-4b).  
 
Figure 2-4 Interaction effects between antibiotics and temperature based on growth after 24-h. The 
interaction effect (~ε) values are color-coded in a gradient, from synergy (red) to additive (gray) and 
antagonism (green). a. Overall distribution of the mean estimated interaction effects across all treatments. 
The distribution shows three clear peaks, corresponding to strong synergy, additivity, and antagonistic 
buffering. b Matrix heatmap of the mean interaction effects. Antibiotics with the same mechanism of action 
show similar interaction patterns. c Matrix heatmap of the discretized interaction types used for constructing 
the edges of the interaction network.  
 
 
Erythromycin and clindamycin (ERY, CLI) exhibit the opposite pattern: they are mostly 
synergistic with lower temperatures and antagonistic with temperatures near the optimum or higher, 
except for 44°C. Furthermore, fluoroquinolones (LVX, CPR), tetracycline (TET), nitrofurantoin 
(NTR), and trimethoprim (TMP) are more synergistic with both low and high temperature 
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extremes, and they are either additive or slightly antagonistic with intermediate temperatures. All 
interactions were calculated using the mean growth under each condition (see Methods 2.2).  
 
Gene expression dynamics after exposure to antibiotics and high temperatures 
Next, we explore the molecular mechanisms involved in the response to antibiotics by 
evaluating genome-wide transcriptional dynamics after exposure to high temperature (44°C) and 
two representative drugs that clustered with temperatures: TET (22–37°C, cold cluster) and STR 
(46°C cluster). To do this, we measure fold changes in gene expression compared to a control 
condition (37°C) with a library of E. coli strains containing GFP fused to more than 1800 
promoters [66]. Consistent with the drug-temperature clusters, we find that the overall gene 
expression at 44°C is more similar to the response to STR than to TET (Figure 2-5a). 
We also look at the expression of some canonical genes from the heat-shock and cold-
shock responses (Figure 2-5b). We find that cspA and cspG, main regulators of the cold-shock 
response, are over-expressed only in response to TET, while cspB and cspI are under-expressed. 
We find that rpoH, the main regulator of the heat-shock response is over-expressed compared to 
control only in the 44°C condition and is under-expressed upon exposure to TET. However, 
chaperones involved in the heat-shock response (dnaJ, dnaK, groE, grpE) show increased 
expression under both STR and TET. This indicates that components of the heat-shock response 
are being activated in response to both antibiotics, while the cold-shock response is activated only 
for TET (a drug from the low temperature cluster). Analysis of gene ontology terms shows that 
genes involved in the response to unfolded proteins, which is a well-known effect of high-
temperature stress, are induced in response to STR (Figure 2-5c). 
 
Figure 2-5 Gene expression of E. coli after exposure to antibiotics and high temperature. The gene 
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expression response of E. coli was evaluated with a library of 1870 fluorescent transcriptional reporters. a 
Mean absolute gene expression distance between experimental conditions. Lower numbers indicate 
conditions with more similar gene expression profiles. b Gene expression of representative heat-shock and 
cold-shock genes relative to control (37°C) in response to experimental conditions (44°C, STR, TET). c 
Gene ontology terms in the biological process category over-represented in the set of over-expressed and 
under-expressed genes in each experimental condition relative to control. Terms that are in bold occur in 
more than one treatment. 
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Changes in antibiotic sensitivity for heat-adapted E. coli strains 
Our above experiments evaluate the overlap between the existing responses of wild-type 
E. coli to antibiotics and temperature. It is also of interest to evaluate if there is cross-resistance 
between temperature-adapted strains and antibiotics. Previously, Rodríguez-Verdugo et al. [67] 
adapted an E. coli strain for over 2000 generations at 42.2°C and showed the heat-adapted strains 
acquired resistance to rifampicin. The resistance phenotype was mapped to mutations in the rpoB 
gene [67]. We profile 10 of the heat-adapted strains, their ancestor strain, and 3 different rpoB 
mutants exposed to the antibiotics used in the clustering experiment. As predicted from our 
clustering analysis, most heat-adapted strains are as or more resistant to antibiotics (NTR and TMP) 
that mimic the effects of high temperatures (44°C) (Figure 2-6a, b). Resistance to aminoglycosides 
(which clustered with 46°C, a much higher temperature to the one the heat-adapted strains were 
evolved on) was higher in some temperature-adapted strains and lower in others. Moreover, 
compared with the ancestor strain, most heat-adapted strains are more sensitive to antibiotics that 
mimic the effects of cold temperatures such as protein synthesis inhibitors (CLI, ERY, TET) 
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(Figure 2-6a, b). These results are based on changes in IC50, the antibiotic concentration that 
results in 50% growth. 
 
Figure 2-6 Antibiotic sensitivity of high-temperature-adapted E. coli strains. a Absolute change in the IC50 
(μg/mL) relative to the ancestral strain. Heat-adapted strains (red), rpoB mutant strains (purple). Error bars 
represent 95% credible intervals (CIs). Gray region represents the 95% CI of ancestral strain. Drugs are 
grouped according to the clusters of antibiotics and temperature in (Figure 2.2). Conditions where the model 
fit was poor were removed from the plots. b Heatmap of log2 fold changes from the ancestral IC50. Heat-
adapted strains are denoted by HA, while rpoB mutant strains are denoted by M. Positive numbers (yellow) 
indicate increased IC50 (more resistance), while negative numbers (blue) indicate a decreased IC50 (higher 
sensitivity). Drugs are grouped in the same way as in a. Missing conditions are shown in white. 
 
 
Intriguingly, the same patterns were not observed for the rpoB mutants exposed to some drugs 
(e.g., for ERY, CLI). These mutants were not adapted at high temperature, suggesting that there 
are additional adaptive mutations in the heat-adapted strains besides rpoB. 
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2.4 Discussion 
 
In this paper, we cluster interactions among drugs and temperatures to infer that there are 
shared physiological responses of E. coli to these stressors. Our SIN analysis suggests that the 
stress responses to low temperatures overlap with those of antibiotics that affect DNA gyrase and 
a 30S protein synthesis inhibitor. In addition, the stress responses to high temperatures overlap 
with those of drugs that affect protein translation proofreading and drugs that damage DNA. Due 
to this overlap, we conclude that cellular responses to temperature stress have likely been 
evolutionarily co-opted to also respond to many classes of antibiotic stress. Because pressure and 
pH are also ancient stressors, we expect that responses to them may have also been co-opted to 
deal with antibiotic stress. Our approach provides a powerful basis for asking similar questions 
about other environmental, chemical, or physical stressors that affect the population growth of an 
organism. 
We show that monochromatic clustering successfully separates antibiotics and temperatures into 
groups that have similar effects on bacterial physiology (Table 2-2).  
 
Table 2-2 Effects of temperature and antibiotics in cellular physiology 
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First, all temperatures (22°C, 25°C, 30°C, 37°C) lower than the optimum (41°C, which 
results in the highest growth) cluster with antibiotics that either affect the early stages of protein 
synthesis (TET prevents the association of aminoacyl tRNAs with the ribosome [69]) or are DNA 
gyrase inhibitors (LVX, CPR). This is consistent with the known effects of low temperature. One 
of the main effects of cold shock is translational block, which is thought to most likely occur at 
the translation initiation step [70]. Some previous reports have also shown that cold-shock induces 
the expression of DNA gyrase and a transient increase of negative supercoiling of DNA in E. coli 
[70-72]. Second, the highest evaluated temperature (46°C) clusters with the aminoglycosides, 
antibiotics that affect protein translation proofreading [68]. This leads to misfolding and 
aggregation of defective proteins that mimic the well-known effects of high temperatures on 
protein stability and folding [49]. Finally, 44°C clusters separately from 46°C, with antibiotics that 
either damage nucleic acids or inhibit their synthesis. This intriguing finding suggests the main 
physiological effect of this temperature (compared to 41°C) could be due to effects on nucleic 
acids. This connection to nucleic acids is suggestive given that the heat-shock protein Hsp70 
enhances repair of UV-induced DNA damage [73]. We speculate that this specific temperature 
clustering separately from the aminoglycosides may be due to the heat-shock response being able 
to partially combat protein unfolding at 44°C, but not 46°C.  
An important feature of the monochromatic clustering framework is that it implicitly 
assumes each node (i.e., stressor) in the SIN belongs to a single cluster. This single cluster 
assumption is likely a good approximation for antibiotics as they tend to bind to specific cellular 
targets. However, physical or environmental stressors, such as temperature, can affect many 
cellular processes simultaneously. Because of this, the clusters in our study correspond to 
consensus effects: these are informative summaries of the dominant effects of the environmental 
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stressor, but could miss secondary effects that are not shared with the other members of the cluster. 
Further theoretical and computational work could focus on relaxing the single cluster assumption 
of monochromatic clustering to allow temperatures to be grouped with multiple, potentially dis- 
similar classes of antibiotics. This updated methodology could allow a more nuanced approach, 
capable of breaking down the effects of an environmental stressor in terms of more targeted 
perturbations such as antibiotics, chemical inhibitors, or gene deletions that are deleterious to 
different cellular subsystems. 
Indeed, some of the evaluated temperatures do have similar interactions to antibiotics in 
different clusters (Figure 2-7). Examples are the lowest temperatures evaluated (22°C, 25°C). 
These temperatures have similar interaction profiles to both the 30S (TET) and 50S (ERY, CLI) 
protein synthesis inhibitors, while higher temperatures that are still below the optimum (30°C, 
37°C) are only similar to the 30S inhibitors. This is reflected in (ERY, CLI) being in a separate 
cluster from the low temperatures. Interestingly, low temperatures cluster with CLI under no salt 
conditions (Figure 2.3), and a previous report has shown cold-shock proteins are induced in 
response to CLI [74]. 
Figure 2-7 Dissimilarity of interactions. A heatmap with the dissimilarity between the interactions of each 
pair of conditions (see Methods 2.2) is shown. The dissimilarities are color coded in a gradient from white 
(more similar) to dark blue (more dissimilar). From these results, it is apparent that temperatures can be 
similar to multiple classes of antibiotics.  
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Clinically, the impact of temperature on the effects of antibiotics is also of interest because 
it suggests some antibiotics could have increased or reduced effectiveness in patients with fever or 
hypothermia. Previous work has shown there is increased resistance to gentamicin (GEN) in 
Francisella tularensis, Listeria monocytogenes, and Klebsiella pneumoniae at 26°C when 
compared to 37 °C [58]. This increased resistance seems to be mediated by reduced drug uptake. 
It has also been reported that streptomycin (STR), tetracycline (TET), ampicillin (AMP), and 
cefoxitin (FOX) have increased effectiveness at 46°C compared to 37°C in Pseudomonas 
aeuriginosa [75]. Our results are consistent with both reports, as we found: (1) aminoglycosides 
(GEN, STR, TOB) are mostly synergistic with high temperatures and antagonistic with low 
temperatures, (2) synergy of beta-lactams (AMP and FOX) with high temperatures, and (3) 
synergy of TET with 46°C (but, interestingly, with 22°C as well). Some other antibiotics (LVX, 
NTR, and TMP) also exhibit this curious pattern of being synergistic with both temperature 
extremes and either additive or slightly antagonistic with less stressful temperatures. Further work 
is needed to obtain a more detailed understanding of these interaction patterns. 
Our transcriptional analysis shows that the overall expression patterns of E. coli exposed 
to high temperature are more similar to those induced by STR than those induced by TET (Figure 
2-5a). We find that cspA and cspG, main cold-shock response regulators in E. coli, have increased 
expression in response to TET, but not STR or high temperature (Figure 2-5b). Other cold-shock 
regulators (cspB, cspI) show decreased expression. It has been shown that cold-shock genes are 
differentially induced depending on the severity of the cold stress. In particular, cspA expression 
is induced between 20–30°C, while cspI is induced between 10 and 15°C [76]. These gene 
expression results are in agreement with our drug/temperature clusters, since the low temperature 
cluster contains temperatures between 22 and 37°C. We find that genes involved in the response 
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to unfolded protein (as determined by gene ontology annotations), which commonly results from 
heat stress, are overrepresented in the genes induced by STR, a representative antibiotic that 
clustered with heat (Figure 2-5c). Interestingly, some heat-shock response genes that combat 
unfolded protein stress (dnaK, dnaJ, groE, grpE) have increased expression in response to both 
STR and TET. However, the main heat-shock response regulator rpoH is not over-expressed in 
response to either antibiotic (in fact, is under-expressed in response to TET). Together, these 
results suggest heat-shock genes participate in the response to both antibiotics. However, they may 
be activated in a different way than the canonical heat-shock response. 
Our clustering and gene expression results show that multiple antibiotics (particularly 
aminoglycosides, TET, DNA gyrase inhibitors, and DNA-damaging antibiotics) have similar 
overall effects in E. coli physiology to specific low or high temperatures. This is consistent with 
components of the stress response to temperature having been co-opted over evolutionary time to 
deal with antibiotics that disrupt similar cellular structures or functions to those affected by low- 
and high-temperature stress. Moreover, we show that this overlap between stress responses can be 
related to the acquired cross-resistance of temperature-adapted strains to specific groups of 
antibiotics. 
Typically, the overlap between cellular responses to stress has been studied by isolating 
subcellular parts and attempting to piece together this information to understand stress responses 
at the whole-cell level. Here, we take a reverse, yet complementary approach: by studying the 
effect of perturbations on the whole system, we gain more insights into the mechanisms of its 
specific parts. Importantly, no aspect of this methodology is specific to antibiotics and temperature. 
Our SIN clustering method can be used to evaluate shared responses among any combination of 
physical, chemical, and/or biological stressors that affect organismic growth. 
 27 
In conclusion, we evaluate if the overlap between antibiotic and temperature stress 
responses is predictive of the cross-resistance of high-temperature-adapted strains to antibiotics 
(Figure 2-6). We find that high-temperature-adapted strains become more sensitive to protein 
synthesis inhibitors (CLI, ERY, TET), drugs that either clustered with or are similar to low 
temperatures. In contrast, the temperature-adapted strains become more resistant to drugs that 
clustered with 44°C (NTR, TMP), but not necessarily to drugs that cluster with 46°C (GEN, STR, 
TOB). Overall, these results strongly suggest that seemingly novel drug resistance is conferred to 
strains via adaptations they acquired while being evolved at extreme temperatures. Specifically, 
strains adapted to heat (42.2°C) are more resistant to drugs that damage DNA (which cluster with 
44°C, a similar temperature), while also being more sensitive to drugs that mimic the effect of cold. 
However, this pattern is not universal, since the strains do not become more sensitive to 
fluoroquinolones (LVX, CPR), which also cluster with cold. Interestingly, the rpoB mutants do 
not follow the same antibiotic resistance patterns as the temperature-adapted strains, suggesting 
there may be more adaptive mutations to temperature besides rpoB. 
 
2.5 Acknowledgements  
 
We thank Bobby Tofig for the laboratory assistance at the facility of Molecular Screening Shared 
Resource at UCLA. 
  
 28 
CHAPTER 3 
How Antibiotics Shift Temperature Response of E. coli 
 
3.1 Introduction  
 
Many environments experience daily and seasonal temperature fluctuations that affect rates 
of physiological processes. These changes in turn affect biological and ecological traits and 
ultimately impact the behavior of communities [77-85]. In this manner, temperature fluctuations 
can drive the evolution of organisms through variation in thermal sensitivity—the ability to 
function and survive at different temperatures [81, 86-91].  
At a cellular level the performance of an organism across different temperatures can lead 
to various genetic and physiological adaptation mechanisms. For example, in bacteria thermal 
sensitivity is related to many physiological and genetic modulations in metabolism, including outer 
membrane rigidity [92, 93], chemotaxis [94, 95], enzymatic thermo-stability [96, 97], and other 
general adaptive responses [49, 98]. Moreover, the heat shock response—a cellular mechanism to 
deal with the deleterious effects of high temperatures, such as protein misfolding and 
aggregation—is highly conserved in both prokaryotes and eukaryotes [49, 99]. Understanding 
responses to temperature changes is important to infer general patterns of how organisms, species, 
communities, and ecosystems are adapting to fluctuations in climate patterns and different 
environmental conditions. 
Thermal sensitivity patterns and the performance of organisms across different 
temperatures are classically represented by the optimal temperature at which the organism 
performs best (i.e., attains its maximum growth) and the thermal breadth (sometimes referred to 
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as performance breadth), which describes the temperature range at which the organism can exhibit 
some level of functioning (Figure 3-1a). These two key parameters are fundamental to grasping 
the variability of physiological and ecological traits in response to temperature changes in different 
taxonomic groups and habitats. Because shifts in the thermal response curves are representative of 
average fitness performance and temporal niches [100], optimal temperature and thermal breadth 
are indicative of evolution and acclimation patterns based on how species’ performance 
contributes to survivorship or fecundity [89]. For instance, seasonal variation in temperature could 
lead to an evolution of different attack and escape speeds that would allow individuals to perform 
best when they are predator or prey [101].  
 
Figure 3-1 Temperature response curves change under antibiotic stress. (a) An example of a left shift of 
optimal temperature with antibiotic GEN. (b) An example of a right shift of optimal temperature with 
antibiotic ERY. (c) Optimal growth temperature (middle dot) and temperature niche (thin line joining the 
half-maximal growth temperatures, left and right dots) observed under each antibiotic used in this study. 
Point estimates for the optimal and half-maximal growth temperatures are shown as dots. To show the 
uncertainty in the estimates, 95% credible intervals (CIs, see Materials and Methods) are drawn as thick 
lines. The CIs for the no drug condition are shaded in the plot to facilitate comparison. 
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Temperature can interact with other environmental stressors such as light, precipitation, 
pH, and salinity. Exposure to different stressor types and intensities can lead to a phenotypic 
variation in an organism’s ability to respond to temperature changes [102, 103]. Nevertheless, how 
the effects of environmental stressors interact with temperature responses is not well understood. 
Therefore, insights on whether temperature responses—as described by optimal temperatures and 
temperature breadths—can change rapidly and plastically in the presence of other environmental 
stressors have been lacking. In fact, it has been commonly assumed that thermal responses are not 
altered in the presence of other stressors [104-106]. A systematic approach that informs how 
optimal temperatures and temperature breadths are shifted by stressors (Figure 3-1) is needed to 
uncover these ambiguities and provide additional insights on fitness trade-offs and thermal 
adaptation strategies. 
Here, we use a combined empirical-theoretical approach to study if the characteristics of 
thermal response curves change in response to additional environmental stressors. In particular, 
we use an experimental system of Escherichia coli and antibiotics as stressors in order to 
investigate how a physiological trait—growth of the bacterium—responds to variation in 
temperature in the presence of different stressor conditions. We obtain temperature response data 
for E. coli in 12 single-drug and 66 two-drug combination environments, where antibiotics are 
chosen to cover a wide range of mechanisms of action (Table 3-1). We then quantify both the 
optimal temperature and the temperature breadth of E. coli in the presence of these different 
environments.  
 
Table 3-1. List of antibiotics. The antibiotics used are listed with their abbreviation, mechanism of action, 
dose, and our color scheme throughout the paper. Similar colors are chosen for drugs belonging to the 
same class for mechanism of action. For example, colors of blue tones are chosen for aminoglycosides. 
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Antibiotic  Abbreviation Color Mechanism of Action Dose 
 (g/mL) 
Ampicillin AMP  cell wall synthesis inhibitor 1.2 
Cefoxitin FOX  cell wall synthesis inhibitor 1.2 
Levofloxacin LVX  fluoroquinolone, DNA gyrase inhibitor  0.01 
Ciprofloxacin CPR  fluoroquinolone, DNA gyrase inhibitor  0.005 
Nitrofurantoin NTR  DNA damaging, multiple mechanisms 2 
Trimethoprim TMP  folic acid synthesis inhibitor 0.1 
Tobramycin TOB  aminoglycoside 1.5 
Gentamycin GEN  aminoglycoside 1 
Streptomycin STR  aminoglycoside 2 
Clindamycin CLI  protein synthesis inhibitor, 50S 40 
Erythromycin ERY  protein synthesis inhibitor, 50S 50 
Tetracycline TET  protein synthesis inhibitor, 30S 0.25 
 
 
We first show that individual stressors can have a substantial impact on the optimal 
temperature and temperature breadth. Next, we evaluate if the directions of the shifted thermal 
responses are related to the mechanism of action of the antibiotics. Previously, we determined that 
some specific classes of antibiotics have similar physiological effects to either heat or cold stress 
in E. coli [107]. We find that in most cases the direction of the shifts in the thermal responses under 
antibiotic stress can be explained through these groups. Lastly, we investigate how pairs of 
stressors move optimal temperatures in different directions as compared to the optimal 
temperatures under single-stressor conditions. In particular, we evaluate the extent to which the 
optimal temperatures result from integrated effects of both stressors, or whether a single stressor 
is the key driver of the temperature response. We infer from our results that a single drug often 
plays a dominant role in determining the optimal temperature response of a combined treatment.  
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Our experimental and theoretical framework on temperature response curves of E. coli 
presented here allows us to better understand how thermal sensitivities change in response to 
stressors. Therefore, our analysis will shed light on fundamental features shaping the ecological 
and evolutionary responses of organisms facing complex environmental conditions. By using 
antibiotics as stressors and a bacterium as a model organism, our study system is particularly 
valuable for its experimental tractability and reproducibility. 
 
3.2 Materials and Methods 
 
Bacterial strain and growth medium  
The study used BW25113, a derivative of the F-, λ-, E. coli K-12 strain BD792 (CGSC6159) [65]. 
Bacterial cultures were grown in LB broth (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) 
and maintained in 25% glycerol at -80°C. Fresh cultures were started by adding 20μL of thawed 
bacterial glycerol stock into 2 mL of LB followed by incubation at 37°C. Cultures were grown to 
exponential growth phase and diluted to maintain 104 cells per experimental condition. 
Antibiotics 
A total of 12 antibiotics were included in the study as representatives of all major drug classes. 
Ciprofloxacin (CPR) from MP Biomedicals (Santa Ana, CA) and Gentamycin (GEN), 
levofloxacin (LVX), tetracycline (TET), tobramycin (TOB), erythromycin (ERY), ampicillin 
(AMP), clindamycin (CLI), streptomycin (STR), nitrofurantoin (NTR), cefoxitin (FOX), and 
trimethoprim (TMP)—all from Sigma (St Louis, MO)—were used. Stock solution at 20 mg/mL 
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of each antibiotic was stored in 50μL aliquots at −20°C. Each aliquot was only frozen and thawed 
once to preserve potency.  
Growth experiments 
Antibiotics used in all experiments inhibited bacterial growth at sub-lethal concentrations (50% to 
90% growth). The desired concentrations were first determined by a twelve step concentration 
series of 2-fold at each step in 96-well plates (Costar). Antibiotic stock solutions were prepared in 
a total volume of 5 mL at 10-fold of their respective concentrations (Table 3-1). Experiments of 
pairwise drug combinations were prepared by adding 10μL of each component drug followed by 
the addition of 80μL cell inoculum. 10μL of LB medium was added in replacement of a second 
drug for single drug experiments. Each experimental condition was conducted in 4 replicates from 
the same antibiotic stock solution. The plates were incubated at various temperatures (22°C, 25°C, 
30°C, 37°C, 41°C, 44°C, 46°C) with aeration at 300 rpm. Cell density was measured at 4-hours, 
8-hours, 12-hours and 24-hours by reading at OD600 nm. The optical density measurements (used 
as a proxy for bacterial growth) at 24-hours were used to infer the temperature curves. 
Extended Briere model for characterizing temperature response curves 
Briere [108] defines a simple model for the temperature dependence of a trait, such as growth, 
denoted by 𝑔(𝑇) as follows:  
𝑔(𝑇) = 𝑐(𝑇 − 𝑇𝑚𝑖𝑛)(𝑇 − 𝑇𝑚𝑎𝑥)
1
2 
where  𝑇𝑚𝑖𝑛 , 𝑇𝑚𝑎𝑥 are the minimum and maximum temperature of growth. This equation can be 
solved analytically to show that the optimal temperature yielding maximum growth is always 
attained at 𝑇𝑜𝑝𝑡 =
2
3
𝑇𝑚𝑎𝑥 +
1
3
𝑇𝑚𝑖𝑛. This model is not flexible enough to describe the antibiotic 
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growth curves we found empirically. As a more general alternative, we propose an extended Briere 
model  
𝑔(𝑇) = 𝑐(𝑇 − 𝑇𝑚𝑖𝑛)
𝑎(𝑇 − 𝑇𝑚𝑎𝑥)
𝑏 
where 𝑎, 𝑏 ≥ 0 are parameters that determine the shape of the curve. In this extended Briere model 
of temperature dependence of a trait, we have 𝑇𝑜𝑝𝑡 = 𝛼𝑇𝑚𝑎𝑥 + (1 − 𝛼)𝑇𝑚𝑖𝑛. In this model the 
optimum temperature can lie anywhere between 𝑇𝑚𝑖𝑛 and 𝑇𝑚𝑎𝑥  depending on the value of the 
fraction 𝛼 ≔  
𝑎
𝑎+𝑏
.  
The extended Briere model can be reparametrized as  
𝑔(𝑇) = 𝑔𝑚𝑎𝑥 [(
𝑇 − 𝑇𝑚𝑖𝑛
𝛼
)
𝛼
(
𝑇𝑚𝑎𝑥 − 𝑇
1 − 𝛼
)
1−𝛼
(
1
𝑇𝑚𝑎𝑥 − 𝑇𝑚𝑖𝑛
)]
𝑠
 
where 𝑔𝑚𝑎𝑥  is the maximum value of the trait, i.e. growth, and 𝑠 = 𝑎 + 𝑏 is a parameter that 
determines the smoothness of the temperature response curve. We use this parametrization for 
parameter fitting of temperature response curves of the bacterium across different drug 
combination treatments (see Table 3-1 for chosen drugs in our study). 
Bayesian parameter fitting  
The extended Briere model was fitted to the temperature growth curve for the bacterium under all 
conditions through a Bayesian methodology with the pymc3 library of the Python programming 
language [109]. The following methodology is used for obtaining Bayesian estimates for the model 
parameters. Let 𝑦𝑖  be the 𝑖 th observed data point for growth after 24 hours and let 𝑇𝑖  be the 
temperature at which it was observed. The observed values were assumed to be Gamma distributed 
with 
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𝑦𝑖| 𝑔(𝑇𝑖), 𝜎𝑇𝑖  ~ Gamma(𝜇 = 𝑔(𝑇𝑖),   𝜎 =  𝜎𝑇𝑖)  
where the Gamma distribution is parametrized in terms of the mean, 𝜇, and standard deviation, 𝜎. 
The data are clearly heteroskedastic, and multiple measurements were taken at the same 
temperature enabling estimates of the standard deviation at each measured temperature. Because 
of this, a different standard deviation was modeled for each measured temperature. The following 
hierarchical model was used for the standard deviation: 
𝜎𝑇𝑖  | 𝛽 ~ ℎ𝑎𝑙𝑓𝐶𝑎𝑢𝑐ℎ𝑦(𝛽) 
 𝛽~ℎ𝑎𝑙𝑓𝐶𝑎𝑢𝑐ℎ𝑦(0.3) 
A variational method (full-rank ADVI) [110] was used to obtain approximate posterior 
distributions for the model parameters. These posterior distributions were used to construct point 
estimates—the expected value of the posterior distribution—and 95% credible intervals for all 
parameters to evaluate the uncertainty in the estimates. Credible intervals are the Bayesian analog 
to confidence intervals. A credible interval contains the true value of the parameter of interest with 
the specified (e.g. 95%) probability, given the observed data. 
Models for predicting optimal temperatures for multi-drug responses  
We denote single drugs as X and Y, and the combination of drugs as XY. We use these drug 
notations as a subscript for the corresponding optimal temperatures, i.e. 𝑇𝑜𝑝𝑡,𝑋, 𝑇𝑜𝑝𝑡,𝑌, and 𝑇𝑜𝑝𝑡,𝑋𝑌 . 
For predicting the optimal temperature of multi-drug combination treatments, we define five 
different models by the choice of simple yet biologically meaningful scenarios (Figure 3-2).  
(i) A single drug is playing a major role in determining the optimal temperature of the 
bacterial response. The optimal temperature of the combination is given by either of 
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the two individual stressors (min or max model). 𝑇𝑜𝑝𝑡,𝑋𝑌 = min(𝑇𝑜𝑝𝑡,𝑋 ,  𝑇𝑜𝑝𝑡,𝑌)  or 
 𝑇𝑜𝑝𝑡,𝑋𝑌 = max(𝑇𝑜𝑝𝑡,𝑋,  𝑇𝑜𝑝𝑡,𝑌). 
(ii) The optimal temperature of the bacterium in the presence of drug combinations is 
shifted to lower or higher temperatures than both single drugs’ optimal temperature 
values. Along the lines of these extreme behaviors, we define attenuated and elevated 
optimal temperature models 𝑇𝑜𝑝𝑡,𝑋𝑌 ≪ min(𝑇𝑜𝑝𝑡,𝑋,  𝑇𝑜𝑝𝑡,𝑌)  or 𝑇𝑜𝑝𝑡,𝑋𝑌 ≫
min(𝑇𝑜𝑝𝑡,𝑋,  𝑇𝑜𝑝𝑡,𝑌). 
(iii) Temperature tolerance is determined by both of the drugs in the combination. To 
uncover such cases, we define our fifth model, namely the mean optimal temperature 
model. This model expresses the optimal temperature of the combined treatment as the 
average of the two single drug optimal temperatures (Fig 3.1). In other words, the mean 
model is equivalent to 𝑇𝑜𝑝𝑡,𝑋𝑌 =
(𝑇𝑜𝑝𝑡,𝑋+𝑇𝑜𝑝𝑡,𝑌)
2
. 
 
Figure 3-2 The optimal growth temperature under stressor combinations is often determined by a single 
stressor.  (a) Schematic illustration of models to determine the optimal growth temperature under two 
stressors (𝑇𝑜𝑝𝑡, 𝑋𝑌
) given the single stressor optimal temperatures (𝑇𝑜𝑝𝑡, 𝑋
, 𝑇𝑜𝑝𝑡, 𝑌
). (b) The frequency 
at which each model is the best fit, across all drug combinations. (c) Proportion of time each antibiotic is 
the main driver of the optimal temperature when combined with other antibiotics, based on the individual 
models: min, max, attenuated, and elevated. 
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To determine the best optimal temperature model, we measured the difference between the 
actual value and the predicted value of each of the min, mean, and max models. We considered the 
best-fit model as the one with the smallest absolute difference between actual and predicted values. 
When this absolute difference is greater than the cutoff value of 2.20°C (Figure 3-3), then the best 
model is determined to be either the attenuated or elevated model depending on the direction of 
the optimal temperature shift. 
 
Figure 3-3 Threshold for distinguishing single-driver models (min versus attenuated or max versus 
elevated). The distribution of model prediction errors across the min, mean, and max models is plotted to 
decide a cutoff to determine if the optimal temperature shift of a pairwise combination is large enough to 
decide the attenuated or elevated models are a better fit. When the prediction error (as defined by an absolute 
value of difference of optimal temperature prediction and actual optimal temperature) is higher than 2.20 °C, 
the best model is either the attenuated model or elevated model based on the direction. 
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3.3 Results 
 
In this paper, we investigate how different stressors (antibiotics) alter an organism’s 
response to temperature, both in isolation and in combination. To do this, we determine the 
temperature optimum and temperature niche/breadth of E. coli by fitting the extended Briere model 
(see Materials and Methods 3.2) to experimental data of bacterial growth collected under different 
(unstressed and stressed) growth environments across multiple temperatures (22°C, 25°C, 30°C, 
37°C, 41°C, 44°C, 46°C). The entire dataset and model fits are shown in Figure 3-4.  
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Figure 3-4 Full dataset and model fits. Lower half: The growth data for all antibiotic combinations (blue 
dots), as well as the fitted extended Briere model (black lines), are shown, as well as 95% credible intervals 
for the extended Briere model. The upper left corner corresponds to the no drug case. Upper half: The fitted 
curves corresponding to each drug combination are shown in black, and the fits corresponding to each single 
drug are shown in their corresponding color. In the uppermost row, the growth curve in the absence of 
antibiotics is shown in black and the single drug curves are shown in the corresponding color. 
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First, we explore how the optimal growth temperature and temperature breadth of E. coli 
change under single-stressor conditions (Figures 3-1a, b). We find that the majority of the single-
drug environments exhibit left shifts—meaning the optimal temperature is lower — (Figure 3-1c) 
compared to the no-drug condition, 𝑇𝑜𝑝𝑡 = 37.7℃, CI: (36.7℃, 38.6℃). Right shifts are both less 
common and of lower magnitude than the observed left shifts. We also find that the thermal niche 
breadth typically becomes narrower under antibiotic stress. 
Next, we investigate whether the physiological effects of antibiotics bear any relation to 
the direction of the observed shifts in the temperature responses (Figure 3-5). To do this, we group 
the antibiotics according to the similarity of their physiological effects to those of low or high 
temperatures, as determined previously [111]. We observe the direction of the shifts for both single 
drugs (Figure 3-5a, left panels) and drug combinations that contain one or more of the antibiotics 
in the group (Figure 3-5a, right panel). We find that—for both single drugs and combinations—
cold-similar antibiotics (i.e., with effects on bacteria similar to those caused by low temperatures) 
tend to either leave the optimal temperature unchanged or shift it slightly to the right (i.e., to higher 
optimal temperatures). In contrast, heat-similar antibiotics (i.e., with effects on bacteria similar to 
those caused by high temperatures) tend to result in unchanged optimal temperatures or shifts to 
the left (i.e. to lower optimal temperatures). In fact, bacteria exposed to aminoglycosides (TOB, 
GEN, STR), which induce misfolding of membrane proteins and have similar physiological effects 
to very high temperatures (Figure 3-5), show the greatest shifts towards the left. This is not the 
case for other protein synthesis inhibitors such as ERY or CLI that are similar to cold. Interestingly, 
beta-lactams shift the temperature curves in a similar way to heat-similar drugs when used in 
combinations, despite them having a different mechanism of action (inhibition of cell wall 
synthesis) that was not found to be heat-similar.  
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We then compare the optimal temperature and temperature niche—the range between the 
temperatures that result in half-maximum growth—for bacteria under all antibiotic combinations 
to the single drug conditions (Figure 3-5b). For some antibiotics (e.g. ERY, CPR) the optimal 
temperature and the thermal niche range are similar to those of the single drug when combined 
with most other antibiotics. In contrast, there are other antibiotics for which these features show 
much more variation when combined with others (e.g. GEN, STR, TOB, FOX). This suggests that 
some antibiotics may act as the main drivers of the temperature response curve of antibiotic 
combinations. 
Figure 3-5 Physiological effects of antibiotics predict the direction of shifts in the optimal temperature. (a) 
Left: The fitted temperature response curve in the presence of single antibiotics is compared to the 
unstressed growth condition. Drugs are grouped according to the similarity of their effects to temperature 
[111], as shown in the top of the plots, except beta-lactams which did not show similarity to temperature. 
Right: Histogram of shifts in the optimal temperature under all pairwise drug combinations involving the 
drugs in the group. The individual estimates are shown as lines in the bottom. The unstressed optimal 
temperature is shown as a dotted line in both sets of plots. For both single drugs and combinations, the 
direction of the optimal temperature shifts depends on whether the drug is similar to cold or heat. (b) 
Optimal growth temperature and temperature niche observed under each antibiotic combination used in this 
study. The first drug in the combination is shown at the top of the plot. The second drug is shown in the y-
axis using its assigned line color. The CIs for the single drug conditions are shown with shaded 95% credible 
intervals to facilitate comparisons. Conditions where the maximum growth was too small to estimate 
parameters reliably were removed. 
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Following this idea, we further explored how the optimal growth temperature is determined 
under combinations of stressors relative to the optimal temperature under single stressor conditions. 
We contrast the observed optimal temperatures with the predictions of five candidate models of 
how the combination optimal temperature could be determined from that of the single stressors 
(see Material and Methods 3.2, Figure 3-2a). The min and max models assume that the optimal 
temperature of the combination is determined by the optimal temperature of a single drug (the 
minimum or the maximum of the pair, respectively). These models best describe most (65%) 
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multi-drug combinations (Figure 3-2b).  The attenuated and elevated models assume that the 
optimal temperature of the combination is either lower or higher, respectively, than for both single 
drugs. These models best describe 18% of the combinations. Lastly, the mean model assumes that 
the temperature of the combination is determined by the average of the single drug optimal 
temperatures. This model best described only 17% of the drug combinations. These results suggest 
that the optimal temperature of antibiotic combinations is often determined by a single drug. 
Finally, we explore cases where single-driver models (min, max, attenuated and elevated) 
represent the best optimal temperature model over the mean model, where both stressors 
compromise to result in the optimal temperature of an organism in the presence of combined 
stressors (Figure 3-2c). Interestingly, we rarely observe aminoglycosides (GEN, STR, TOB), 
antibiotics similar to high-heat, being drivers. In contrast, some cold-similar drugs (ERY, LVX, 
CPR), but not others (CLI, TET), frequently drive the optimal temperature of the combination.  To 
account for the possibility that some antibiotics appear to be a driver more often than others purely 
by chance, we used a permutation test to evaluate our data against the null model that all drugs are 
equally likely to be a driver. This test provides strong evidence (p=0.002) that some antibiotics 
have a greater tendency to be drivers than others by testing the entire dataset simultaneously. We 
also tested if specific antibiotics are drivers more often than expected by chance. However, we did 
not obtain statistically significant results for individual drugs, after correcting for multiple 
comparisons. We believe this may be due to a lack of statistical power to detect differences due to 
the smaller number of observations for individual antibiotics when compared to the full dataset.  
 
 
 
 44 
3.4 Discussion 
 
Through a systematic analysis of growth response curves of bacteria across different 
temperatures and under different stressor environments, we investigate the effects of stressors on 
the phenotypic variation in temperature response traits—optimal temperature and temperature 
niche breadth. We see that stressors often decrease the temperature breath and shift the optimal 
temperature in a direction that depends on their physiological mechanism of harm. In addition, our 
results suggest that left shifts—where the optimal temperature in a stressed environment is lower 
than the optimal temperature in unstressed environmental conditions—are more common and 
dramatic as opposed to right shifts towards higher optimal temperatures.    
High temperature harms living organisms through multiple mechanisms, including 
misfolding and aggregating proteins, damaging nucleic acids and increasing membrane 
permeability [49]. The heat shock response attempts to prevent and/or repair this damage by 
producing chaperones that aid the correct folding of proteins [112]. It has previously been shown 
that certain kinds of antibiotics can activate components of the heat-shock response [111, 113]. 
However, adding antibiotics to heat stress is unlikely to help the cell survive high temperatures, 
since the heat-shock response is already induced by the high temperature alone. Thus, right shifts 
in the optimal temperature may be rare because it is unlikely that adding a second stressor can 
reduce or repair the high-temperature induced damage. In most cases where we do observe a right 
shift, it seems to be due to asymmetrical effects on the temperature response curve, where the left 
portion (i.e. below the unstressed optimal temperature 𝑇𝑜𝑝𝑡) is more depressed by the antibiotic 
than the right portion (Figure 3-4, Figure 3-5a).  
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In contrast, cold temperatures predominantly slow down cell growth by suppressing DNA 
replication or protein translation [114, 115]. Since the effects of low temperature seem to be 
primarily mediated by slowing down metabolism and growth rather than the accumulation of 
physical damage, it seems more likely that stressors can shift the optimal temperature to the left, 
especially when the stressor is more harmful at higher temperatures. In some cases, cold 
temperatures might allow cells to sustain antibiotic killing because certain antibiotics are only 
effective against actively growing cells [116]. Low temperatures have also been shown to alter the 
structural stability [117] or the global uptake of some antibiotics such as gentamicin, thus 
impairing killing efficiency [118]. 
Based on network clustering methods [63, 119], we previously found that certain antibiotic 
classes have similar physiological effects to either heat or cold in E. coli [111]. These temperature-
drug groups were also shown to correlate with changes in drug sensitivity of high-temperature 
adapted strains obtained by Rodríguez-Verdugo et al [67]. Interestingly, here we find that in most 
cases the direction of the shifts in the optimal temperature can be predicted from these groups. 
Cold-similar drugs tend to either leave the optimal temperature unchanged, or to shift it slightly to 
the right. In contrast, heat-similar drugs tend to result in larger shifts to the left or leave the optimal 
temperature unchanged (Figure 3-5). Similar trends are exhibited by antibiotic combinations 
containing drugs in these groups. We propose that this phenomenon can be explained in the 
following way: the overlap in the physiological effect of the drugs and the corresponding 
temperature stress (heat or cold) causes increased damage to similar cellular functions (e.g. 
aminoglycosides and high temperatures simultaneously present will result in more misfolded 
proteins than either stressor on its own). When a drug is added, this could “overload” the stress-
response machinery of the cell at less extreme temperatures, causing a greater reduction in growth 
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when the temperature damage overlaps with that of the drug. The cases with the most pronounced 
shifts in optimal temperature tend to have lower peak growth (Figure 3-5a). This suggests that 
perhaps these shifts become more pronounced when increasing the antibiotic concentration. Hence, 
we hypothesize that increasing the concentration of heat-similar drugs will result in greater shifts 
to the left and that doing so for cold-similar drugs will result in greater shifts to the right.  
Notably, although the aminoglycosides (TOB, GEN, STR) share the same cellular target—
the ribosome—as the other protein synthesis inhibitors (CLI, ERY, TET) used in our study, they 
result in distinct effects on the thermal response. Previously, differences in the effects of 
aminoglycosides and other protein synthesis inhibitors at different growth rates have been 
attributed to the reversibility of ribosomal binding [120]. In that study, the authors found that STR 
is more effective when the growth rate is lower, which does not agree with our results at low 
temperatures. This discrepancy may be because the reduction in growth was previously 
manipulated by nutrient limitation as opposed to the temperature variation in our study. Instead of 
binding reversibility, we could explain the different effects of these drugs by their mechanisms of 
action being qualitatively different, with the aminoglycosides being heat-similar and the other 
protein synthesis inhibitors being cold-similar. This is because aminoglycosides, unlike other 
protein synthesis inhibitors, induce mistranslation by the ribosome that decreases translational 
accuracy and causes protein misfolding [121]. Cold temperatures may counteract this effect by 
slowing down ribosomal activity and increasing accuracy [74], thus causing aminoglycosides to 
be less effective when bacterial growth is suppressed at lower temperatures, as we observe. 
Reduced drug uptake at low temperatures could also play a role [118]. Interestingly, beta-lactams 
have a similar effect in the temperature response as heat-similar drugs. We speculate that this may 
be due to increased effectiveness at high temperatures due to a synergy between the cell wall 
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damage caused by the antibiotic and the increased membrane permeability caused by high 
temperatures. Further disentangling these processes in future studies will help to understand the 
connection between antibiotic susceptibility and bacterial physiology. 
We find that the breadth of the temperature niche is typically reduced in the presence of 
antibiotics, both in isolation and in combination. The lower and upper limits of growth are believed 
to be set by chemical and physical limits on the biological processes necessary for bacterial 
physiology, growth and cell division [81]. As such, this result is perhaps expected, since it is 
unlikely that adding a second stressor can increase this temperature range. However, we see the 
range can be reduced if the stressor is more harmful at either temperature extreme.  
The optimal temperature of E. coli in the presence of antibiotic pairs often moves in a 
direction that is mostly determined by a single antibiotic. In a work on green algae, growth 
response to multiple environmental drivers has been shown to be dominated by the response to a 
single driver [122]. That study showed growth could be predicted for environments with a high 
number of interacting stressors if a severely detrimental driver was present. Environments with a 
smaller number of factors that involve temperature, CO2, and pH suggested that specific 
interactions between responses determined overall growth rather than the response to an overriding 
factor. In contrast, we see effects on optimal growth temperature due to both a dominating driver 
and the interaction between drivers. For example, aminoglycosides (TOB, GEN, STR) show the 
largest degree of downshifting of the optimal temperature. However, when a second drug is added, 
this downshifting tends to be alleviated. Thus, in combinations of stressors, aminoglycosides are 
not the dominant driver for changing optimal temperature despite their large effects when used 
alone. Therefore, identifying a dominant environmental driver can be a simplified approach to 
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understanding organismal response to a complex system, but it needs to be done with care since 
interactions between drivers can be a contributing factor as well.  
Our findings on single-stressor effects on thermal responses are surprising, especially in 
terms of optimal temperatures. Most models for the thermal optimum—the temperature at which 
the maximum growth is attained—posit that the optimum is below the mean environmental 
temperature by an amount determined by temperature variability in the environment [104-106]. It 
is tacitly assumed that the optimum temperature of individuals is thus either genetically hardwired 
or set through development to closely align with these predictions and thus be determined by 
environment in which the individual has been reared and the species has evolved. For this reason, 
the optimal temperature could be expected to be static when experiencing other stressful conditions. 
Nevertheless, against these expectations, in our data we observe that stressors can substantially 
change the optimal temperature for growth. On the other hand, organisms experiencing selection 
for greater adaptability traits to temporal changes could exhibit physiological plasticity with 
broader temperature breadth to adjust with various environmental stressors [100].   
Although there has been substantial interest in understanding thermal response curves 
because of their potential to predict responses to climate change [101, 123, 124], the implications 
might be even broader. For example, an intriguing recent study showed that increased local 
temperatures were associated with increasing antibiotic resistance [125]. This may be because 
temperature or seasonality effect environmental growth of resistant strains [126, 127] and 
horizontal gene transfer—one method of facilitating resistance transmission [128, 129]. Another 
study showed the impact of chronic or long-term temperature changes unexpectedly coincided 
with spontaneous mutations against rifampicin resistance, an antibiotic that impairs RNA 
polymerase [67]. Climate change has also been linked to the impact on host-parasite dynamics that 
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alters the frequency and severity of many infectious diseases [130, 131]. Our work here and 
elsewhere shows that certain classes of antibiotics are more effective at different temperatures, and 
that there is substantial overlap in the response mechanisms to temperature and some kinds of 
antibiotics. This suggests the hypothesis that climate change might favor the evolution of 
resistance of specific (e.g. heat-similar) antibiotics indirectly by their resistance to high 
temperature stress. 
From our results it appears that drugs can be used to modify temperature response curves 
in predictable ways. A temperature-drug system could perhaps be used to examine scenarios for 
biological responses to climate change via a variety of thermal responses. These experiments could 
be performed in a laboratory setting, which would enable the use of high-throughput platforms and 
a large number of replicates. Going forward, our system could serve as a simplified model for 
examining changes in response to temperature across seasons, geographic gradients, and climate 
change.  
Temperature is one of the fundamental drivers of biological processes. By using antibiotics 
as stressors, our study system is particularly valuable for its tractability, reproducibility, and 
potential to study temperature-stressor interactions beyond the pairwise level. Our results on 
temperature response curves under combinations of antibiotics provide insights into the 
evolutionary adaptation of organisms to changes in temperature and what drives these adaptations. 
Investigating stressor effects on the physiological and ecological trait responses to temperature 
changes under this framework could lead to future research directions in exploring other 
environmental stressors that may aid in predicting the stability and diversity of ecological systems.  
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CHAPTER 4 
Transitions in Interaction Landscapes of Multidrug Combinations 
 
4.1 Introduction 
 
Combination therapy is widely used to treat a number of chronic health issues such as 
cancer [132, 133], HIV [134, 135], hypertension [136], or multidrug resistant bacterial infections 
[137, 138]. Understanding the effects of these drug combinations and interactions among drugs is 
a major clinical concern and active research area [139-147] . Effectively leveraging interactions of 
drug combinations can be a promising strategy for combatting the evolution of drug resistance. 
However, a detailed understanding of how multiple drugs interact in a dose-specific manner is 
challenging to examine and visualize. Gaining this understanding is critical both for devising 
optimal treatments and for leveraging selection pressures to combat evolution of resistance. 
Measures for interactions are often evaluated based on a coarse-grained categorization of 
three interaction types: additive (no interaction), synergistic (combined effect greater than 
expected based on single-drug effects), and antagonistic (combined effect less than expected based 
on single-drug effects). Synergistic drug combinations—in which combining drugs enhances the 
effects of the individual drugs—are commonly prescribed for patients because they maximize 
efficacy at lower doses. However, previous work indicates that antagonism may be more beneficial 
for slowing down the rate of resistance evolution to the component drugs [141, 144]. Thus, simply 
knowing how interactions deviate from additivity towards synergy or antagonism is potentially a 
powerful indicator to anticipate effects of a specific drug combination on treatment and resistance 
development.  
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Nevertheless, in practice it becomes challenging to use this interaction categorization to 
optimize treatment strategy and leverage evolution of resistance due to the complexity of dose-
dependent interactions. Many empirical studies of drug interactions are conducted at a fixed dose 
and thus can only measure a single interaction type for each specific drug combination (i.e., Bliss 
Independence) [141, 142, 148]. The Bliss independence model is one of the most commonly used 
measures of drug interactions because it is intuitive, simple to calculate, readily expandable to 
numerous interacting components, and experimentally less demanding because it only requires 
four measurements—the control with no drug, drug x, drug y, and drug x, y combined—to classify 
a pairwise interaction.  
When interaction type changes as drug dose is varied [149], the common interaction 
definitions based on single-dose measurements break down because it is incorrect to apply a single 
interaction type to that specific drug combination. Changes in interactions based on doses is well 
known for combinations of antibiotics, antifungal, and chemotherapeutic agents [148, 150-153]. 
This suggest interactions are not properties of drug combinations but drug concentrations. But our 
question is: Is this dose-dependency a second-order correction of slight importance, or does it 
represent substantial and significant deviations that would be difficult to capture by a nonlinear 
(but monotonic) null model? Moreover, does this depend on the particular drugs used, the 
extremeness of the concentrations, or net versus emergent interactions? More systematic studies 
are needed to find and understand general patterns and thus to avoid adverse effect that promote 
development of resistance and disease relapse. Such cases could occur when the interaction of a 
drug combination is defined at a specific dose combination and is extrapolated into a region of 
drug doses where the interaction is neither what is expected nor what is desirable. Until now, there 
have been no direct and intuitive visualizations of high-dimensional drug spaces to help verify and 
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more deeply understand the range of complexities in transitions among interaction types and 
whether drug interactions “switch” type or have a “phase transition” in type or whether they 
smoothly transition.  
In this paper, we describe a new approach to visualize and analyze interaction data--
interaction landscapes and various companion methods—and to present results on higher-order 
drug-interactions in a pathogenic Escherichia coli strain by examining all possible three-drug 
combinations among 8 antibiotics, each varied across a range of 7 concentrations. We specifically 
focus on changes in interaction type, precisely because we are looking for substantial and 
significant changes—not second-order corrections—that are more qualitative than quantitative and 
are thus likely to be found by most any null model. We introduce a new and direct visual 
representation of dose-dependent drug interactions that we term “interaction landscapes”. This 
approach is placed directly within the space of drug interactions where general inferences about 
consequences of interactions can be made quickly with extremely efficient use of the information 
in the data. Interestingly, because interactions are calculated from fitness differences, the 
interaction landscape is a visual representation that partly captures directions and strengths of 
selection pressures. Therefore, these interaction landscapes will help to analyze how drug-dose 
combinations affect treatment strategies, regions of positive or negative selection pressures, and 
evolution of resistance. 
Interaction landscapes, which are based on our high-throughput data and calculated from 
our mathematical framework, provide direct visualizations of local synergy or antagonism 
embedded within a larger interaction space and thus enable quantification and assessment of the 
directionality, pervasiveness, organization, and transition between regional synergy and 
antagonism. Consequently, we can use these landscapes to carefully investigate and answer the 
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questions above. We expect broad implications of this general approach and ideas, including in 
environmental pollution and risk assessment of toxic chemical mixtures where the exposure is 
rarely a uniform dose. 
 
4.2 Materials and Methods 
 
Bacterial Strain 
We used E. coli CFT073, a highly virulent pyelonephritis strain isolated from human clinical 
specimen, obtained from ATCC (designation number 700928). The strain was grown in 2 mL of 
LB media (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) and streaked onto LB agar plates 
to isolate single colonies. Then a single colony was inoculated into 2 mL of LB and grown for 24 
hours. Following the incubation, the culture was mixed with 2 mL of 50% glycerol and aliquoted 
into 50 L to generate bacterial cell stocks with 25% glycerol for storing at -80C. Each experiment 
was started with a thawed aliquot stock by inoculating 20 L into 2 mL of LB media. The culture 
was incubated at 37C until it reached exponential growth phase (an OD of 0.5) and diluted to 
maintain 104 cells per experimental condition.  
 
Antibiotics 
Antibiotics used include erythromycin (ERY), ampicillin (AMP), clindamycin (CLI), 
streptomycin (STR), nitrofurantoin (NTR), cefoxitin (FOX), and trimethoprim (TMP), all from 
Sigma (St Louis, Mo), and ciprofloxacin (CPR) from MP Biomedicals (Santa Ana, Ca). All 
antibiotics were dissolved and sonicated in 100% DMSO (Sigma) except for STR which was 
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dissolved in 50% DMSO, due to limited solubility in 100% DMSO. Experiments for IC50 and 
drug interactions (below) were conducted in clear flat bottom 384-well plates from Greiner BioOne.  
 
IC50 determination 
A 20-step two-fold serial dilution was prepared for each antibiotic. The source plate was made by 
preparing each drug with a total volume of 70 L at 10 mM as the starting concentration, or the 
first step, filled into a 384 well plate. The following dilution steps were conducted by a robotic 
liquid handling system with a transfer volume of 35 L per step. Meanwhile, 25 L of LB per well 
were prefilled into a second 384-well plates using the Multidrop 384 (Thermo Scientific). Next, 
500 nL from the source plate were delivered into the prefilled plate using the Biomek FX 
(Beckman Coulter) with a pin tool (V&P Scientific). Then, 25 L of bacteria inoculum was added 
to each well to reach a final 50 L per well with 1% DMSO. Each plate included negative controls 
(media alone), vehicle controls (media with 1% DMSO), and positive controls (media with 1% 
DMSO and cells). The plates were incubated at 37C with OD595 measurement for cell density at 
4-hour intervals for 24 hours. IC50s were determined by fitting a sigmoidal dose-response curve 
using the software Graphpad Prism.  This is only used to analyze the preliminary results to 
determine the concentrations of each drug used in the drug combination experiments.   
 
Determining drug-dosage levels from dose-response curve of single drugs 
To establish reasonable resolutions of various drug doses, we designed our dilution regime to cover 
a wide range of dose effectiveness in terms of bacterial fitness of lethal, low, intermediate, and 
high. Mean dose response curves of each single drug show a sigmoidal and monophasic curve that 
results in the desired fitness levels. Dose indices 1 and 2 are regarded as low doses, where fitness 
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is between 1 and 0.8, with fitness here measured as growth rate relative to bacteria in no-drug 
environments. Dose indices 3 to 5 are intermediate doses that give a mean fitness around 0.4. High 
doses of 6 and 7 result in fitness below 0.2, except for clindamycin that has fitness well above the 
other drugs. We then calculated IC95 concentrations—where the dose concentration inhibits 95% 
of bacterial growth compared to no-drug environments—for each single drug (Table 4-1) to 
normalize the combined dose in triple-drug combinations in terms of combined effectiveness. 
 
Table 4-1 List of drugs used in the study 
 
 
 
Drug combination experiment  
All three-drug combinations formed from a set of eight drugs were tested, resulting in 56 unique 
three-drug combinations. Each drug combination was conducted in duplicate. The reproducibility 
is assessed in the supplemental material (Table 4-2). A source plate for each drug was prepared in 
seven-step, two-fold dilutions with various starting concentrations (Table 4-1), dependent on their 
respective IC50, with a total of 70 L in DMSO at each dilution step. In addition, a zero dose was 
included into each drug gradient as the lowest concentration. A combination drug plate was 
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prepared by pinning from each source plate of the component drugs using a 250 nL pin tool (V&P 
Scientific) to restrict the DMSO concentration to be lower than 1%. Methods for cell inoculation 
and incubation were the same as stated above. OD measurements were taken at 12 hours.   
 
Table 4-2 Test for reproducibility of our two experimental replicates. The table on the left shows the 
correlation between our two replicates. The table on the right shows the correlation between any two 
random experiments. Trivial refers to conditions where in a three-drug combination, the concentration of 
at least one of the three drugs is zero. 
 
 
 
 
 
 
 
Measuring fitness 
Optical density measurements were made with Perkin Elmer Wallace 1420. Fitness was calculated 
as 
 
𝑊 = (𝑂𝐷 − 𝑂𝐷𝑛𝑒𝑔)/(𝑂𝐷𝑝𝑜𝑠 − 𝑂𝐷𝑛𝑒𝑔), 
 
where OD is the optical density of the experimental condition with bacteria and drugs, ODpos is the 
positive control without drugs, and ODneg is the negative control without bacteria or drugs. Fitness 
is given with a precision of two decimals, and we therefore exclude fitness measurements below 
0.01.  
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Quantifying interactions 
Interactions are commonly quantified as the deviation from Bliss independence [64]. We quantify 
this using deviation from additivity (DA), which measures interactions between drugs, while 
additivity is defined when the presence of one drug does not affect the percent reduction of 
bacterial growth of another drug, using Bliss independence as a null model. If the fitness of the 
organisms given three drugs is  𝑊𝑋𝑌𝑍, and the fitness when only given one drug is 𝑊𝑋,  𝑊𝑌, and 
𝑊𝑍, for drugs X, Y, and Z, respectively, then [154]. 
 
𝐷𝐴 =  𝑊𝑋𝑌𝑍 − 𝑊𝑋𝑊𝑌𝑊𝑍 
 
DA incorporates both pairwise and three-way drug interactions but cannot discern between them. 
To measure emergent interactions that occur only when three drugs are present, we subtracted both 
the single-drug effects and the component pairwise effects [154].   
 
𝐸3 =  𝑊𝑋𝑌𝑍 − 𝑊𝑋𝑊𝑌𝑍 − 𝑊𝑌𝑊𝑋𝑍 − 𝑊𝑍𝑊𝑋𝑌  +  2𝑊𝑋𝑊𝑌𝑊𝑍  
 
Pairwise effect, or DA2, is calculated as 
𝐷𝐴2 =  𝑊𝑋𝑌 − 𝑊𝑋𝑊𝑌 
 
To delineate boundaries and tease apart interactions as synergistic, additive, or antagonistic from 
the unimodal distribution of DA and E3, rescaling was applied to each measurement. DA was 
rescaled by dividing by the absolute value of DA, but replacing 𝑊𝑋𝑌𝑍 (denoted as ?̃?𝑋𝑌𝑍) by 0 if 
DA ≤ 0, to account for cases of extreme lethal synergy (𝑊𝑋𝑌𝑍 = 0) while no single drug completely 
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was completely lethal, and by the minimum value of 𝑊𝑋, 𝑊𝑌, 𝑊𝑍 if DA > 0, for cases of buffering 
antagonism where combined drugs have the same effect as the strongest single-drug effect.  
 
𝐷𝐴𝑅  =  (𝑊𝑋𝑌𝑍 − 𝑊𝑋𝑊𝑌𝑊𝑍)/|?̃?𝑋𝑌𝑍 − 𝑊𝑋𝑊𝑌𝑊𝑍|, 
 
where ?̃?𝑋𝑌𝑍 = 0 for DA ≤ 0 and min(𝑊𝑋, 𝑊𝑌, 𝑊𝑍) otherwise.  
 
Similarly, E3 is rescaled by dividing by  
 
|?̃?𝑋𝑌𝑍  + 𝑊𝑋𝑊𝑌𝑍 + 𝑊𝑌𝑊𝑋𝑍 + 𝑊𝑍𝑊𝑋𝑌  −  2𝑊𝑋𝑊𝑌𝑊𝑍|, 
 
where ?̃?𝑋𝑌𝑍 = 0 for E3 ≤ 0 and min(𝑊𝑋𝑊𝑌𝑍 , 𝑊𝑌𝑊𝑋𝑍 , 𝑊𝑍𝑊𝑋𝑌) otherwise [154]. This rescaling 
results in values between -1 and ∞. We further discretize both DAR and E3R based on the natural 
breaks in the histogram distribution of DAR and E3R . Values below -0.5 correspond to synergy, 
between -0.5 and 0.5 to additivity, and above 0.5 to antagonism. Values above 1 are capped at 1. 
 
DA2R, the pairwise DA is rescaled as ?̃?𝑋𝑌 =  (𝑊𝑋𝑌 − 𝑊𝑋𝑊𝑌)/|?̃?𝑋𝑌 − 𝑊𝑋𝑊𝑌|, where ?̃?𝑋𝑌 = 
min (𝑊𝑋, 𝑊𝑌) for 𝑊𝑋𝑌 >  𝑊𝑋𝑊𝑌 and is 0 otherwise. For 𝑊𝑋𝑌 > min (𝑊𝑋, 𝑊𝑌),  ?̃?𝑋𝑌 =  (𝑊𝑋𝑌 − 
min (𝑊𝑋, 𝑊𝑌))/(1 −  min (𝑊𝑋, 𝑊𝑌)) + 1.  
 
Smoothing 
To increase resolution of interaction transition with dose—given the fairly noisy OD 
measurements—we smoothed the data using a weighted average algorithm by considering our 
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dose combination matrix as a metric space. For each data point (interaction measurement at each 
drug-dose combination), both rescaled DA and E3 were recalculated as a weighted average 
depending on the Euclidean distance (within the three-dimensional matrix) between the original 
data point and the points used for calculation. The weight is 1 for the origin, and 1/8d for the 26 
nearest neighbors, where d is the Euclidean distance from the origin. If a neighboring value was 
missing, either because it lies at the boundary or because it was excluded due to low fitness, its 
weight was set to zero. The sum of the weights was required to comprise at least 59 percent of the 
original weight matrix. For smoothing, both DA and E3 were truncated to values between -1 and 
1, with higher values set equal to 1. 
 
4. 3 Results 
 
Overall, we find that interaction types are often strongly dose-dependent, and that this is 
true for both lower-order (two drug) and higher-order (three drug) combinations.  We typically 
observe smooth transitions between different interaction types and subspaces within a drug 
combination. Furthermore, net interactions tend to transition from synergy at low dose to 
antagonism at high doses. For emergent interactions, higher doses often have the opposite effect 
and lead to more antagonism. These transitions happen quickly but smoothly. Finally, pairwise 
interactions can often be used to predict net three-drug interactions but not emergent three-drug 
interactions.  
 
Interaction type is dose dependent and regionally confined.  
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Both lower-order (2-drug) and higher-order (3-drug) interactions are strongly dose 
dependent. To assess the effect of increasing dose on interaction in a two-drug case, we compared 
how one drug (at a specific dose) interacts with another drug at either a high dose or a low dose. 
In a three-drug combination, the interaction was examined with two drugs at a specific dose while 
the third drug was added at a high or a low dose. For combinations of 3 drugs, we measured 
interaction both at the overall net level (DA)—combined pairwise and three-way interactions—
and at the emergent level (E3), where the pairwise interactions are subtracted from the net 
interactions so that only the truly three-way interaction part remains (Figure 4-1b). We then plotted 
the interaction measurements in a 3-dimensional matrix or the interaction landscape (Figure 4-1c). 
As shown in Figure 4-1c, the interaction landscape for the combination of AMP, CLI, and ERY 
presents a mixture of synergistic (red) and antagonistic (green) regions as dosage is varied. In 
addition, the landscapes of DA and E3 are not entirely superimposable in terms of the regional 
interactions, meaning that a specific drug-dose combination can give rise to different landscape by 
including or excluding certain interacting components.  
Figure 4-1 Schematic representation of experimental design. (A) For one triple-drug combination of X, Y, 
and Z, the drug X plate includes 7 steps of 2-fold serial dilutions (in red) plus no drug control (in white) 
going in the horizontal direction. Drug Y plate includes the same concentration gradient but in the vertical 
direction (in blue). Combining drug X and drug Y plates results in a 2-dimensional matrix of drug X+Y. 
Drug Z is composed of 7 plates each with one concentration across the full 7-drug gradient (in green). Each 
of the seven drug Z plates is transferred to a drug X+Y plate to form a matrix of X+Y+Z at one respective 
dose (drug X+Y+Z). Finally, a 3-dimensional matrix of all three drugs is constructed of all seven additions 
of Z into one plate of X+Y, plus a control where Z is zero. (B)  For each drug-dose combination, the overall 
interaction of DA is calculated with the three subsets of pairwise interactions of drug X+Y, drug X+Z, and 
drug Y+Z with each at a specific dose denoted as n (2), and the interaction when all three drug are present 
(3); while emergent three way E3 represent the interaction of only at the three drug level.  (C) Construction 
of the interaction landscape with DA and E3 measurements. Each three-dimensional matrix represents a 
three-drug combination, each data point is plotted with the overall interaction (DA) or emergent three way 
(E3). The color scale represents the degree of interaction from -1 to 1. Red and green indicate synergistic 
and antagonistic interactions, respectively. Additivity (i.e., no interaction) with values between -0.5 to 0.5 
were not plotted. The two interaction landscapes are shown as examples for the different net (DA) and 
emergent (E3) interactions of the drug combination AMP/CLI/ERY.   
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The distinction between DA and E3 is intriguing. Although each is calculated from a 
different metric, the null model for E3 expects no measurable interaction (in this case an empty 
landscape) if the overall interaction completely equates to the lower-order components so that they 
cancel each other. Although interactions change with dose, these changes tend to be confined to a 
smaller dose space, rather than being completely random. Furthermore, the pattern is not specific 
to certain drug combinations but more widely holds true. We also note the effect of smoothing on 
the landscapes as we compare them in parallel, in a representative drug combination (Figure 4-2).  
 
Figure 4-2 Three-dimensional interaction landscapes for a representative triple drug combination. DA or 
E3 as a function of the dose of each of three drugs. Rescaled values (top row) and smoothed values (bottom 
row) for DA (left column) and E3 (right column) for each drug-dose combination. Markers are color coded 
from bright red for synergy (DA = –1) to bright green for antagonism (DA = 1). Additive interactions (–0.5 
< DA < 0.5) have been excluded. In drug combination AMP-CLI-ERY, the smoothed values show that DA 
is predominantly antagonistic at lower doses and synergistic at higher doses. The pattern changes when we 
only include three-way interactions (E3), for which antagonism generally dominates, and there is minimal 
correspondence between regions of antagonism in DA and E3. In drug combination AMP-CPR-CLI, the 
difference between the predominantly synergistic interactions in DA switches to almost exclusively 
antagonistic in E3. Notably, there is no correspondence between DA and E3, indicating that DA is driven 
by the pairwise interactions while the three-way emergent interactions measured by E3 are independent of 
the pairwise interactions.  
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Smoothing dampens the noise by averaging out the interaction measurements with its 
neighboring points so the interactions are, on the whole, weakened. But the general patterns in the 
landscape remain (in terms of the synergistic and antagonistic regions) when the signal is above 
the noise level. The distributions of DA and E3 among all combinations of drugs and doses are 
multimodal with peaks at synergy (DA = –1), additivity (DA = 0), and antagonism (DA = 1) (Figure 
4-3a, b). Smoothing the data results in a more continuous distribution (Figure 4-3c, d). The peaks 
at the boundaries of synergy and antagonism are much less prominent (Figure 4-3c, d), and low 
drug concentrations result primarily in net interactions that are additive or antagonistic (Figure 4-
3). Synergistic DA and E3 interactions are mostly observed at intermediate and high concentrations 
with a dearth at low doses (Figure 4-3c, d). 
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Figure 4-3 Rescaled net (DA) and emergent (E3) interaction distributions. Panel A and C show the overall 
net level (DA) that encompasses all component pairwise and three-way interactions. Panel B and D show 
interaction at the emergent level (E3), where the pairwise interactions are subtracted from the net 
interactions so that only the truly three-way interaction part remains. The colors correspond to drug 
concentration, where IC95 were used as the maxima. Drug concentrations above IC95 were counted as the 
maxima. (A) Rescaled DA, (B) rescaled E3, (C) smoothed DA, (D) smoothed E3. Low drug concentrations 
(red) result predominantly in additive (–0.5 < DA < 0.5) or antagonistic interactions (DA > 0.5). Higher 
concentrations (green to purple) are more evenly distributed among interaction types. 
 
 
 
Interaction type transitions.  
When interaction type changes, net interaction (DA) tends to become more synergistic as 
the combined dose increases, while emergent interaction (E3) becomes more antagonistic (Figure 
4-4).  
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Figure 4-4 Change of interactions of three drug combination as a function of combined dose. Interaction is 
plotted on the y axis and characterized as synergistic (<-0.5), additive (-0.5 to 0.5), and antagonistic (>0.5). 
(A) Change of DA and (B) E3 with dose for each interaction types of antagonistic (green) and synergistic 
(red). For both DA and E3, total antagonism and synergy each increase in magnitude with dose, though the 
effect is smallest for DA antagonism and strongest for DA synergy. 
DA antagonism: Pearson’s ρ = 0.396, p = 0.045. 
DA synergy: Pearson’s ρ = -0.883, p = 5.1e-09. 
E3 antagonism: Pearson’s ρ = 0.951, p =  1.0e-13. 
E3 synergy: Pearson’s ρ = -0.891, p = 2.4e-09. 
Combined dose is the sum of 2 to the power of each of the three dose indices (2x + 2y + 2z), and antagonistic 
lines include all points where DA (or E3) > 0 and < 0 for synergy. 
 
 
 
We counted the number of cases of interaction transitions based on the change in direction 
(e.g., antagonism to synergy) (Figure 4-5). For interaction transition to synergy from a low to high 
dose, we show about 20% occurrence in DA while E3 has only less than 4%.  Most of the transitions 
are from additivity (no interaction) to either synergy or antagonism. Abrupt transitions between 
synergy and antagonism are extremely rare, occurring less than 4% for DA and less than 1% for 
E3. Antagonistic interactions remain antagonistic or becomes additive 26% of the time for 2-drug 
combinations and 17% for 3-drug combinations. Emergent interactions (E3) are rarely synergistic. 
We did not see any emergent synergy at the low dose, while at high dose there is about 4% (Figure 
4-5).  
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Figure 4-5 Distributions of transitions between interaction types from a low dose (index 1) to a high dose 
(index 6). To assess the effect of increasing dose on interaction in a two-drug case, we compared drug 
interaction of drug A at a sub-inhibitory concentration and drug B at either a high dose and a low dose. In 
a three-drug combination, the interaction was examined with a third drug at a high and low dose. Pairwise 
interactions (DA2, i.e. overall pairwise interaction) are dominated by antagonism and additivity at the low 
dose (green and gray, 99%), while a total of 10% are synergistic at the high dose (left). Three-way (DA) 
interactions are mostly additive at the low dose (gray, 76%) and antagonistic (green, 22%), but change from 
additivity to antagonism (16%) and from additivity or antagonism to synergy (21%) at the high dose. The 
emergent three-way interactions measured by E3 are mainly additive at the low dose (gray, 89%) with the 
rest being antagonistic and result in very few synergistic interactions at the high dose (3%), with some being 
antagonistic (22%) and a majority being additive (75%). 
 
 
 
 
Interaction transitions are summarized for each drug combination with both the sum and 
absolute change in DA (Figure 4-7).  
 
Figure 4-6 Changes of interaction from low to high dose in each drug combination. Interaction is calculated 
at both the DA (overall net interaction) and E3 (emergent three way) at each dose combination from lowest 
to highest and the changes are summarized as both the absolute change (top panel) and the overall change 
(bottem panel). (A) Absolute DA changes (top) and total DA change (bottom). (B) Absolute E3 changes 
(top) and total E3 change (bottom). Blue is rescaled data, and red is smoothed data. The total DA changes 
between doses 1 and 6 are positive when the majority changes to become more antagonistic, while those 
that primarily change to synergy are negative. The sum of E3 transitions are nearly all positive, showing 
that three-way interactions almost exclusively change to more antagonism as the dose is increased. 
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Increasing the dose of one drug can lead to no change, additive to synergy, or additive to 
antagonism (Figure 4-7). Again, the landscapes are not randomly scattered with different 
interaction types, but instead are composed of local areas of synergy or antagonism. Transitions 
between different interaction types are generally buffered by a region of additivity, or what we call 
“smooth”. 
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Figure 4-7 Transition trajectory of three-way DA interaction versus doses grouped by transition category. 
From antagonism at dose index 1 (green) to antagonism (199), additivity (556), and synergy (110) at dose 
index 6, from additivity (gray) to antagonism (413), additivity (1885), and synergy (679), and from synergy 
(red) to antagonism (13), additivity (32), and synergy (28). Error bars are s.e.m. 
 
 
 
 
Pairwise interactions contribute most to net three-way interactions. Emergent three-way 
interactions are not predicted by pairwise interactions. 
For each three-drug combination, we calculated three-way net (DA3), pairwise net (DA2), 
and three-way emergent (E3) interaction for drug-dose combinations with a third drug at low, 
intermediate, and high concentrations (dose indices 2, 4, and 6). For all three doses, the mean of 
the three pairwise DA2 correlates strongly with three-way DA3 (Spearman’s ρ = 0.793, Figure 4-
8a). Surprisingly, DA3 and E3 show no correlation (Spearman’s ρ = -0.094, Figure 4-8b), but E3 
and pairwise DA2 exhibit a slightly anti-correlated pattern (Spearman’s ρ = -0.384, Figure 4-8c). 
A more synergistic mean pairwise DA2 thus predicts a more synergistic three-way DA3, which is 
to be expected because the pairwise interactions are included in the three-way DA3. 
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Figure 4-8 Comparisons of three-way interactions to pairwise interactions. For each three-drug combination, 
we calculated three-way net (DA), pairwise net (DA), and three-way emergent (E3) interaction metrics for 
all possible drug pairs and doses with the third drug at low, intermediate, and high concentrations (dose 
indices 2, 4, and 6). The relationship between the three-way DA at dose index 6 and the mean of the three 
pairwise DAs at the same doses shows a strong positive correlation (Spearman’s ρ = 0.793), whereas this 
correlation is absent between E3 and three-way DA, as well as between E3 and the mean pairwise DA. 
Together, this suggests that the E3 interactions emerge independently of the pairwise interactions. The 
pairwise interactions surprisingly are negatively correlated with the emergent three-way interactions. DA 
and E3 are evaluated at a high dose (dose index 6), and markers are colored according to the three-way DA 
value for antagonism (green), additivity (gray), and synergy (red). Three-way DA and E3 are calculated for 
one drug at dose index 6 and the other two drugs at all dose combinations. The three pairwise DA 
components are calculated with one of the three drugs concentrations at zero. The mean pairwise-E3 
correlation for synergy alone is ρ = –0.619. 
 
 
 
We also note that synergistic three-way DA3 (red points) interactions can be driven by 
synergistic E3 while the pairwise DA2 are antagonistic (Figure 4-9).  
 
Figure 4-9 Correlations between the mean pairwise DA and E3. Interactions are antagonistic (green), 
additive (gray), and synergistic (red) for three-way DA. There is a particularly strong correlation between 
mean pairwise DA and E3 for synergisitic interactions. 
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Conversely, E3 can remain predominantly antagonistic when both the mean of the three-
pairwise interactions and the three-way DA3 are synergistic. This effect is likely to result from low 
fitness at high doses that can cause large deviations in DA and E3. The correlations between 
pairwise DA, three-way DA, and E3 are similar for both low and intermediate doses of the third 
drug (dose indices 2 and 4) (Figure 4-10). 
 
Figure 4-10 Correlations between pairwise DA, three-way DA, and E3 using dose index 2 (top row) and 
dose 4 (bottom row). This is similar to the correlation using dose 6 (Figure 4-8). 
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4.4 Discussion 
 
To quantify the effect of dose on drug interactions, we measured fitness of a pathogenic 
strain of E. coli subjected to all possible 3-drug combinations of eight antibiotics across a gradient 
of doses for each drug. To visualize the high-dimensional interaction space of our data, we 
introduced the interaction landscape that displays quantitative measures of interactions as a 
function of the interacting components. We provide evidence that different environmental 
conditions (i.e., drug concentrations) can change drug interaction type and thus lead to dose-
dependent interactions. But within a smaller dose space, interaction types are more consistent, and 
this gives rise to locally synergistic or antagonistic regions. We also showed these transitions are 
smooth, rarely going from synergy directly to antagonism or vice versa. Instead, transitions first 
pass through the intermediate type of additivity (no interaction) as they pass from antagonism to 
synergy or from synergy to antagonism. This is the opposite of what one might expect with 
“smoothing” the data. Smoothing could average over additive regions and make the transitions go 
straight from synergistic to antagonistic, which would then be interpreted as sharp transition. The 
interaction landscapes give a direct and intuitive view of how the environmental space of combined 
drug doses affects the efficacy of drugs in combination. This representation is analogous to other 
maps of underlying control variables onto one dependent variable, such as genotype-fitness maps 
[155-157], genotype-phenotype maps [158, 159], and phenotype-fitness maps [160-162]. It is also 
similar to the analysis of a reaction norm in an ecological sense, since a typical dose response 
curve for a single drug describes the growth pattern across one concentration gradient. In addition, 
we expect our approach can be usefully applied or complementary to other systems or studies 
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related to toxins, pollution, stressors, genetic interactions, or environmental heterogeneity [163-
166].  
Our results lead to two insights that should aid future studies of drug combinations. First, 
within our interaction landscapes, there are large, clearly delineated subspaces that correspond to 
specific types of drug interactions. These subspaces often occur at high or low concentrations of 
the combined drugs. Conclusions can therefore be made with less information than is needed for 
fitness landscapes by mapping the boundaries between these different subspaces and by 
understanding how the magnitude of the interactions change when moving toward or away from a 
boundary. Moreover, these subspaces suggest simple methods for predicting regions of positive or 
negative evolutionary pressures on subpopulations of treated cells (e.g., selecting for or against 
resistance) and could have profound implications for choosing effective drug-dose combinations 
as well as intelligent drug treatments. Second, because there are transitions across the landscape 
that go between these subspaces of interaction type, synergistic combinations identified with only 
one dose regime [63, 141, 144, 148] can be antagonistic when used or prescribed at a different 
dose regime. Such a reversal could have detrimental impact on clinical decisions and scientific 
studies. For example, in Figure 4-1c, an interaction type of antagonism at one set of doses ([ERY]= 
125 M, [AMP] = 0.39 M, and [CLI] = 7.81 M) changes to synergy at another set of doses 
([ERY] = 125 M, [AMP] = 6.25 M, and [CLI] = 125 M). Understanding how drugs interact in 
a dose-specific way will help to avoid conflicting results and potentially detrimental antagonistic 
combinations being applied in the wrong setting [167, 168]. Importantly, fluctuating drug dosages 
could be used to create fluctuating selection pressures for cell populations. Indeed, evolutionary 
dynamics of a population can change drastically in changing environments [169, 170] and 
fluctuating environments can lead to higher levels of genetic diversity and biodiversity [171], 
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evolution of generalist over specialist species [33], and other evolutionary and ecological 
phenomena. To assess whether this picture of drug interactions as strongly dose dependent goes 
beyond these particular drugs for this specific strain of E. coli, other drugs or other organisms need 
to be explicitly examined. Further detailed data and identification of general patterns across 
bacterial strains or drugs will contribute to better methods for predictions and might aid the 
understanding of the underlying mechanisms of these complex interactions, which is currently 
lacking.  
Zimmer et al. [148]proposed a model that predicts higher-order interactions at a full range 
of doses based only on pairwise interactions at low doses. We find component pairwise interactions 
are the largest contributor to overall net interactions, suggesting the approach of Zimmer et al. may 
be frequently useful but with one important caveat that it does not apply to emergent interactions. 
Specifically, we show emergent interactions are independent of pairwise interactions and conclude 
that higher-order emergent interactions are not easily predictable or understood using the 
framework of Zimmer et al. That is, for most of the three-drug combinations, the pairwise DA2 is 
a reasonable predictor of three-way net interaction (DA3), but it does not correlate well with or 
usefully predict E3. Moreover, even net synergistic three-way DA3 is not always predictable from 
component pairwise interactions. Nevertheless, it still is more correlated with E3, demonstrating 
that the net interaction arises from the emergent part as opposed to its lower-order components. 
For such cases, inferences based on the Zimmer et al. model can be especially misleading. This 
critical distinction appears to be absent from the literature, possible because previous studies on 
dose-dependent interactions have been conducted with either limited numbers of drug 
combinations, with drugs at fixed doses, or have analyzed interactions with methods that do not at 
all between distinguish net versus emergent interactions. Our study remedies both the lack of data 
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and missing analysis for emergent interactions for dose dependency. Crucially, our studies 
examine emergent interactions, rather than interactions arising solely from deviations from 
additivity.  
Finally, we acknowledge that examining the whole-drug space for three-drug combinations 
can be extremely time consuming and expensive. An intriguing recent work by Cokol et al. [172] 
sampled data that correspond to a portion of our interaction landscape in order to infer the 
interaction type based on the Loewe additivity model in which it is assumed that a drug cannot 
interact with itself [173]. However, this methodology requires that the interactions be uniform 
throughout the entire interaction space, such that the contours stay either concave or convex across 
all doses. That is, the Cokol et al. framework assumes that there is no dose dependency— meaning 
no transitions between subspaces of interaction types. In contrast, our study using Bliss 
Independence models—which applies to single-dose measurements and makes no assumptions 
about dose dependency—shows that drug interactions generally are strongly affected by dose 
when we look at the entire interaction landscape. These fundamental discrepancies between the 
Bliss and Loewe models are also observed in two-drug interactions [174]. Future work to 
understand the meaning of these differences, which are intricately connected to the domain of Bliss 
versus Loewe models, are therefore greatly needed.  
The advantage of our framework is its ability to disentangle the overall net interactions 
from higher-order emergent interactions that require component drugs to predict and to understand. 
Indeed, intuiting and thus understanding the complexity of drug interactions is aided by our 
introduction of interaction landscapes along with our results that regional synergy and antagonism 
are buffered by additivity and transition smoothly between interaction types. Our results explicitly 
demonstrate and highlight the independence of higher-order interactions from pairwise pieces and 
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urges the careful consideration and evaluation of any predictive approach for studying how higher-
order interactions depend on lower-order components [175, 176].  
Such insight is needed because combinatorial therapy is an extremely common practice in 
complex, chronic diseases such as hypertension, infectious disease, and cancer [177, 178], and 
because it could be strategically valuable and informative for preventing the evolution of resistance. 
Visualization and analysis of multi-dimensional interaction data is a challenge faced by an 
increasing number of disciplines as experimental advances for collecting big data continue to grow. 
By combining our large dataset with a rigorous theoretical framework to quantify both net and 
emergent interactions, our approach enables new insights via the detection and quantification of 
how multi-drug interaction landscapes are structured from low to high doses or for small or large 
numbers of drugs.  
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CHAPTER 5 
Fitness landscapes across environmental gradients reveal changes in the direction and 
magnitude of epistasis 
 
5.1 Introduction 
 
The vision of evolution as a hill climbing process, introduced by Sewall Wright, has 
motivated numerous studies on how organisms move up to higher fitness peaks in a mountainous 
fitness landscape [179, 180]. The concept of the fitness landscape has since been widely used to 
visualize genotype-fitness relationships, and to understand and even predict evolutionary 
dynamics [156, 180-184]. The ability to make accurate predictions varies tremendously depending 
on the topology of the fitness landscapes, including such characteristics as the number of fitness 
peaks, the area of low fitness between peaks or fitness valley, and the smoothness and ruggedness 
of the landscapes [181, 185-188].  
The ruggedness of the fitness landscape is caused by epistatic interactions [189, 190]. 
Epistasis describes the dependence between genes and their genetic background, or gene-gene 
interaction (GxG), and is extremely pervasive, because genes do not function in isolation [181]. It 
can also reveal functional organization and biological modularity of gene-gene interaction 
networks [62, 191]. Ruggedness obscures the fitness consequence of specific genes or mutations, 
and limit the predictability regarding which evolutionary path an organism is likely to take [181, 
185, 192-194]. For example, the fitness cost of antibiotic resistance mutations can be alleviated by 
compensatory mutations, which are essential for the persistence of costly mutations in an 
antibiotic-free environment, where the selective pressure is relieved [195, 196]. This would result 
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in a rugged landscape caused by epistasis between resistance mutations and compensatory 
mutations [195, 196]. Thus, epistasis can drastically shape the accessibility of adaptive trajectory 
of mutations and facilitate or constrain evolution [197-199].   
Compensatory mutations can be one solution to cross a fitness valley, by which an indirect 
evolutionary trajectory is taken [200]. Another proposed solution to crossing a valley involves the 
non-static nature of fitness landscapes [201]. Environmental perturbations can give rise to both 
quantitative and qualitative changes, such as changes in peak height, or cases where a peak 
emerges or submerges. This may allow populations to traverse through a fitness valley, or move 
away from a local fitness peak, but through a different landscape topology. Thus, a fluctuating 
environment may reveal an otherwise maladaptive path in rugged landscapes, enable evolutionary 
rescue, and prevent the population from being trapped in an evolutionary dead-end [201, 202]. 
 Understanding epistatic interactions require understanding how changing environments 
affect these interactions. Some intriguing recent studies have shown how the structures and 
features of fitness landscapes can be profoundly different based on different environments [156, 
170, 182, 183, 203, 204]. But environmental changes are not always abrupt or acute—they can be 
gradual and subtle. For example, antibiotic concentration gradients are present in soils and 
hospitals, and across organs and tissues in treated patients. In fact, environmental heterogeneity in 
the case of bacterial exposure to antibiotics has been proposed to be an important mechanism of 
resistance evolution [205, 206]. Yet there have been few studies that focus on the dynamics of this 
phenomenon, and understanding the changes in fitness landscapes across environmental gradients. 
Our study is designed to examine such changes in fitness landscapes by quantifying the structural 
differences and specifically answering the question of whether it is the extent of environmental 
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change or the type of environmental change that contribute to the difference in fitness landscape 
that we observe.   
Here we analyze empirical fitness landscapes with a set of Escherichia coli mutants 
exposed to a range of concentration gradients from 15 different antibiotics. These concentration 
gradients mimic fluctuating environments either temporally, such as the degradation of antibiotics 
over time, or spatially, where the antibiotics in the environment are not distributed homogeneously. 
We use a suite of quantitative methods to analyze the general features, with emphasis on epistasis 
and landscape ruggedness. We find significantly positive epistasis among five deleterious 
mutations in our reference environment, where no antibiotics is added. We show overall 
ruggedness decreases as fitness decreases in some antibiotic gradients. But the change of 
ruggedness varies by rate and direction in smaller concentration ranges, or by different antibiotics. 
The structural changes of fitness landscapes are difficult to predict, with the appearance and 
disappearance of local fitness peaks being caused both by changing the type and concentration of 
antibiotics. Finally, pairwise epistasis changes both in sign and magnitude from a more rugged to 
a less rugged landscape, in contrast to higher-order epistasis which almost never changes in sign. 
Tuning the level of environmental stress can drive different signs of pairwise epistasis (from 
negative epistasis to positive or vice versa) that either promote specialization by more efficiently 
purging less fit genotypes or maintaining genetic variation as a potential strategy to combat 
environmental fluctuations. 
 
5.2 Materials and Methods  
 
Bacterial Strains 
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We used a collection of Escherichia coli, with a total of 32 strains, which has all possible 
combinations of five mutations (Table 5-1) that were the first to be substituted during a long-
term evolution experiment [22] and were initially used in a previous study on epistasis between 
beneficial mutations [157] The ancestral strain was an E. coli B clone, a commonly used 
laboratory strain for many microbial experimental evolutionary studies [207, 208].  
 
Table 5-1. Five mutations of E. coli used in the study. 
 
Culture and growth condition  
We used LB broth (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl per liter) for cultivating 
and maintaining E. coli strains. The strains were originally evolved in Davis minimal broth with 
0.025 g glucose per liter [209]. For each strain, a single colony was inoculated into 2 mL of LB 
and grown for 24 hours. Following the incubation, the culture was mixed with 2 mL of 50% 
glycerol and 50 L aliquots of the mixture were used to generate bacterial cell stocks with 25% 
glycerol for storing at -80C. Each experiment was started with a thawed aliquot stock by 
inoculating 20 L into 2 mL of LB media. The culture was incubated at 37C until it reached 
Gene or gene 
region 
Abbreviation Type of 
mutation 
Gene 
Description 
Binary code 
rbs r SNP Ribose 
catabolism  
10000 
topA t SNP Topoisomerase I 01000 
spoT s SNP Stringent 
response 
regulator  
00100 
glmUS g Insertion (1bp) Cell wall 
biosynthesis 
00010 
pykF p SNP Pyruvate kinase 00001 
 81 
exponential growth phase (an OD of 0.5) and diluted to maintain 104 cells per experimental 
condition. 
Experimental design 
We subjected all strains to a range of concentrations of antibiotics to create a gradually changing 
environment. The concentration gradients were established with 20 steps of 2-fold dilutions of a 
single antibiotic (Table 5-2). Antibiotics used include erythromycin (ERY), ampicillin (AMP), 
clindamycin (CLI), streptomycin (STR), nitrofurantoin (NTR), cefoxitin (FOX), and 
trimethoprim (TMP), all from Sigma (St Louis, Mo), and ciprofloxacin (CPR) from MP 
Biomedicals (Santa Ana, Ca). All antibiotics were dissolved in 100% DMSO (Sigma) except for 
STR which was dissolved in 50% DMSO, due to limited solubility in 100% DMSO. The 
following preparations were completed with automated liquid handling system in the Molecular 
Screening Shared Resources facility at UCLA. A 20-step two-fold serial dilution was prepared 
for each antibiotic with starting concentration at 100x the experimented concentrations (or the 
starting concentration in Table 5-2) of 70 L in DMSO, filled into a 384-well source plate. 
Meanwhile, 25 L of LB per well were prefilled into a second 384-well plates using the 
Multidrop 384 (Thermo Scientific). Next, 500 nL from the source plate were delivered into the 
prefilled plate using the Biomek FX (Beckman Coulter) with a pin tool (V&P Scientific). Then, 
25 L of bacteria inoculum was added to each well to reach a final 50 L per well with 1% 
DMSO. Each plate included negative controls (media alone), vehicle controls (media with 1% 
DMSO), and positive controls (media with 1% DMSO and cells). The plates were incubated at 
37C with OD595 measurement for cell density at 12 and 24 hours. A total of 38,400 wells were 
screened for each of the 32 strains in 300 distinct environments with 4 replicates.  
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Table 5-2 List of antibiotics used in the study. 
 
Epistasis 
Epistasis between pairs of mutations are calculated as  
ε = log10(W0WAB/WAWB) 
where W0 is the fitness without either mutation, WA is the fitness with mutation A, WB is the fitness 
with mutation B, and WAB is the fitness of the population with both mutations. This results in 
negative epistasis (ε < 0) when the double-mutant has lower fitness than the non-epistatic 
expectation (i.e., W0WAB < WAWB), and positive epistasis (ε < 0) when the combined effect of the 
two mutations yields a higher than expected fitness [210]. 
Extending the pairwise epistasis to epistasis with N mutations is generalized to the following form 
[157]: 
ε = log10(W0WAB … N / WAWB … WN)  
 
Antibiotic Abbreviation Maximum 
concentration 
(mM) 
Minimum 
concentration 
(nM) 
Molecular 
weight 
(g/mol) 
IC50* 
(M) 
Erythromycin ERY 3 5.722 733.93 12.3 
Clindamycin  CLI 3 5.722 461.44 1499 
Levofloxacin LVX 0.25 0.048 361.37 0.24 
Ciprofloxacin CPR 0.25 0.048 385.82 0.06 
Chloramphenicol  CHL 1 1.907 445.18 153 
Tetracycline TET 1 1.907 444.43 0.41 
Doxycycline  DOX 1 1.907 512.94 0.96 
Nitrofurantoin NTR 1 1.907 238.16 - 
Piperacillin  PIP 1 1.907 539.54 0.76 
Spectinomycin SPT 1 1.907 367.00 384.4 
Cefoxitin FOX 1 1.907 449.43 1.37 
Ampicillin  AMP 1 1.907 371.39 1.55 
Trimethoprim TMP 1 1.907 290.32 0.58 
Sulfamonomethoxine SLF 1 1.907 280.30 121.6 
Amikacin AMK 0.125 0.238 585.60 23.45 
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Ruggedness 
Peaks, i.e., genotypes with higher fitness than all their one-mutant neighbors, can be used as a 
proxy for landscape ruggedness [211]. The more rugged a landscape, the more peaks it will 
generally have, whereas a smooth landscape will have just a single peak. To compare the 
ruggedness among different landscapes, we count the average number of peaks within all 
subgraphs of size four. That is, if a landscape has more than four loci, then every four-locus 
subgraph is constructed and the number of peaks is counted. We use the number of peaks because 
it is an intuitive measure of how rugged a landscape is, but emphasize that the number of peaks 
has been shown to correlate with other, less intuitive measures of landscape ruggedness such as 
the steps of adaptive walks to reach a peak that also reflect the relative contribution of epistasis 
[211]. In a smooth landscape with a single peak, the ruggedness is 1.  
 
5.3 Results 
 
Significant antagonistic epistasis in a rugged fitness landscape was observed for the 
antibiotic-free environment. 
Our control, or reference environment was defined as growth in rich media (LB broth). The 
choice of LB broth allowed us to examine a broader range of antibiotic concentrations since 
bacterial growth with antibiotics are generally higher in rich media than it is in minimal media. As 
a result, the effects of all five single mutations, evolved in minimal media, were no longer 
beneficial but deleterious, except for one (pyfK) that remained nearly neutral (Fig 5-1a.). The 
observed fitness landscapes (Fig 5-1a.) were profoundly rugged, with a ruggedness of 3.4. The 
ruggedness is measured by counting the average number of peaks within all subgraphs of size four. 
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Therefore, the maximal ruggedness would be 8, in subgraphs of 4 genotypes. In a smooth 
landscape, ruggedness would be 1. We also calculated the overall epistasis of the antibiotic-free 
environment to be antagonistic with a positive mean at 0.265. An epistasis of 1 means the observed 
fitness for genotypes with more than one mutation was 10 times higher than expected compared 
to a null model of no epistasis. An epistasis of 0.265 means the observed fitness is approximately 
1.84 times higher than expected, which is very large.  
 
Figure 5-1 The observed fitness landscape in an antibiotic-free environment is highly rugged due to 
significant antagonistic epistasis. a. Observed fitness landscape of the reference (antibiotic-free) 
environment, the number of mutations is plotted on the x-axis and fitness is on the y-axis. Fitness is plotted 
as the average of four experimental replicates. b. Expected fitness landscape of the reference environment, 
calculated using a multiplicative null model of epistasis by taking the product of individual fitness effects 
of the relevant mutations. 
 
 
 
Ruggedness of fitness landscape generally decreases as environment gets more stressful.  
We compared how fitness landscapes change over a concentration gradient, with the focus 
on ruggedness. Overall, the fitness of all genotypes decreases with increasing amount of antibiotics, 
 85 
leading to different fitness distributions and distinct topology of fitness landscapes at each 
concentration step (Figure 5-2).  
 
Figure 5-2 The landscape topology and fitness distribution are drastically different with different 
concentrations of a single antibiotic. The fitness landscape is plotted with the number of mutations on the 
x-axis and fitness on the y-axis. The fitness distribution of all genotypes for each landscape is shown on the 
right. Ciprofloxacin (CPR) is added in each condition at 0.006144 M (low antibiotic dose), 0.012288 M 
(intermediate antibiotic dose), and 0.024576 M (high antibiotic dose). 
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Among all 15 tested gradients, in general, ruggedness decreases when environments 
become increasingly stressful (Figure 5-3). However, with low amounts of antibiotics, ruggedness 
tends to fluctuate. In the case of SPT, CHL, and SLF, ruggedness is strikingly constant before a 
sharp decrease. For TMP and CPR, the drop is not as drastic, but ruggedness decreases overall. 
For CLI and ERY, we note a slight increase in ruggedness before the drop. We also see an opposite 
trend for FOX and AMP, where ruggedness seems to increase with increasing antibiotic 
concentrations, following the plateau. As the environment continues to become lethal and fitness 
landscapes flatten, the rugosity of the landscape becomes lower although the landscape can still 
exhibit ruggedness with multiple lower, local fitness peaks. These fitness peaks shift in an 
environmental gradient. For example, genotype 10010 emerged as a peak at sub-lethal 
concentrations, but as the concentrations decreased to a residual level, the peak disappeared 
(Figure 5-4). In comparison, genotype 11111 appears as a local fitness peak and remained as a 
peak through a much wider concentration gradient (Figure 5-4). 
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Figure 5-3 Ruggedness generally decreases when environments become more stressful. Each panel shows 
the change of ruggedness over a 20-step 2-fold concentration gradient for a specific antibiotic. A local 
regression model is used to fit the data, with the shaded area showing the 95% confidence interval.  
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Figure 5-4 The appearance or disapperance of fitness peaks are concentration dependent. CPR is serially 
diluted of 2 fold at each step. Each row corresponds to a concentration of CPR , arranged from highest to 
lowest, gray for lethal concentrations where the mean fitness is less than 0.1, green for sub-lethal 
concentrations, and blue for antibiotic concentrations with no measurable fitness effect. The genotypes are 
aligned on the x axis. A presence of a bar indicates the corresponding genoytpe is a local maximum or 
fitness peak.  
 
 
 
As ruggedness decreases, pairwise epistasis switches sign, where higher-order epistasis 
almost always changes in magnitude only.   
Since ruggedness is caused by epistasis, we next set out to compare epistasis between the 
most and the least rugged landscapes in each concentration gradients. We calculate epistasis with 
any number of mutations (from 2 to 5) and the wild-type is always defined as the genotype with 
none of the five mutations. Among the 15 different gradients, 11 of the most rugged landscapes 
are associated with a higher antibiotic concentration (a more stressed environment) than the least 
rugged landscape. The four exceptions are NTR, FOX, AMP, and AMK. The higher rugged 
landscapes for these 4 cases and TMP also have some genotypes with zero fitness value. Therefore, 
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the epistasis was not concluded and excluded for the figure. For all the other antibiotics, we show 
the ratio of epistasis between a high rugged and low rugged landscape for all possible combinations 
of the 5 mutations and group them by epistasis order (Figure 5-5). In general, epistasis at all orders 
is higher in a more rugged compared to a less rugged landscape. For pairwise epistasis, we see 
some ratio with a negative value, indicating a change in the sign of epistasis. For epistasis beyond 
pairwise (3, 4 and 5 way), we rarely see a change in the sign, but only change in the magnitude.  
 
Figure 5-5 From a high rugged to low rugged landscape over each antibiotic gradient, pairwise epistasis 
changes sign, while higher order epistasis almost always changes in magnitude. Each panel shows one 
specific gradient, with the ratio of epistasis between a high-rugged to low-rugged landscape. In each panel, 
a total of 26 epistatic interactions from all possible combinations of 5 mutations is shown. The interactions 
are grouped of by the number of mutations or the epistasis order, indicated by the number at the top of each 
box. The dotted line is added for a ratio of 1 for no change. 
 
 
 
The switch in the sign of pairwise epistasis from a high rugged landscape to a low rugged 
landscape is specific to a single mutation.   
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To take a closer look at the change in sign of pairwise interaction, we choose LVX as a 
representative, where we see the most sign changes (6 out of 10 pairwise) (Figure 5-6). We also 
included the change of pairwise interactions for all the remaining drugs in the supplemental 
information (Figure 5-7). The switch in epistasis sign does not seem to be consistently in one 
direction (i. e. from negative to positive or vice versa), from a high rugged to low rugged landscape. 
Three out of the six sign changes are from negative in a high-rugged landscape to positive in a 
low-rugged landscape. All three cases involve the same mutation, namely topA (which encodes a 
type of topoisomerase that relaxes DNA supercoiling) where the single mutant is more fit than the 
wild-type at the concentration for higher ruggedness. The rest of the three switches is from positive 
epistasis in a more rugged landscape to negative in a less rugged landscape. Two of them involves 
the mutation of spoT, which encodes a key enzyme in the stringent response that is first recognized 
in starved bacterial cells. The third case of sign switching directions is an exception in the sense 
that it does not involve spoT, but despite the difference in sign, the change is less significant from 
0.08 to -0.051 (Figure 5-6).  
 
Figure 5-6 Pairwise epistasis switches sign from a high rugged landscape to low rugged landscape, over the 
concentration gradient of LVX. All ten possible pairwise epistasis from 5 single mutations is shown. Every 
single mutation is listed by the first letter of the gene for simplicity. The color and the exact value for each 
pairwise epistasis are shown for comparison.  
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Figure 5-7 Pairwise epistasis switches directions from a high rugged landscape to low rugged landscape, 
over the concentration gradient of various drugs. All ten possible pairwise epistasis from 5 single mutations 
is shown. Every single mutation is listed by the first letter of the gene for simplicity. The color and the exact 
value for each pairwise epistasis are shown for comparison.  
 
 
 
5.4 Discussion  
 
Through a suite of quantitative analyses of fitness landscapes, we examined the changes of 
landscape topology upon gradual fluctuations of various environmental gradients. Not surprisingly, 
the degree of structural change depends on the magnitude of environmental fluctuations. As the 
environments get increasingly stressful, the fitness of all genotypes decreased towards zero. Some 
genotypes are more sensitive in that their fitness approached zero faster, leading to a regional 
collapse of the fitness landscapes, meaning the landscapes typically do not collapse in a whole but 
in parts first. The ruggedness of the landscapes generally decreases with the fitness decrease over 
a large gradient, although the rate and direction of change are specific to the stressor (antibiotic). 
Along with the change of ruggedness, the underlying change of epistasis is complex. Particularly, 
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pairwise epistasis changes frequently in both the magnitude and sign, where higher order epistasis 
almost never changes in sign and only change in magnitude. Moreover, the sign switches of 
pairwise epistasis typically involves the drastic fitness difference of a single mutation from one 
antibiotic concentration to another. Our results suggest epistasis can be a potential force to drive 
different evolutionary strategies between promoting specialization with positive pairwise epistasis 
and maintaining genetic variation with negative pairwise epistasis.  
In recent years, technological advances in molecular biology such as genetic manipulations 
and sequencing have made empirical work on fitness landscapes possible. Many studies have 
revealed general patterns including the significance and pervasiveness of epistasis and its 
environmental dependency [156, 157, 170, 180, 181, 183, 185, 203]. Environmental change is one 
of the most important stochastic factors that affect evolution. Therefore, to understand or even 
predict the process of evolution through the lens of the fitness landscape requires considering the 
environmental change. Here we are motivated by the question of how much environmental change 
needs to be considered, whether it is the extent of change or the type of change that matters.  
A recent study on multi-environment fitness landscapes of a tRNA gene of yeast compared 
the fitness correlation between an optimal growth environment and three perturbed environments 
with cold, heat and oxidative stress [183]. The fitness of mutants in each environment was 
generally well correlated, with similar fitness landscape across the examined conditions. But the 
difference in correlation appeared to be hierarchical, depending on the extent of environmental 
variation. For example, fitness correlation was much higher between the cold-stressed and 
reference environment than it was between a cold-stressed and heat-stressed condition. Another 
study from Matsui et al. also noted the magnitude of environmental effect on gene interaction was 
dependent on the severity of environmental perturbation [212]. Other studies on fitness landscapes 
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of antibiotic resistance genes in bacteria have shown dramatically different landscapes with 
different antibiotics (environments) or the concentrations of antibiotics (degree of environmental 
fluctuations) [170, 203]. Mira et al. concluded that the effect of changing the concentration of an 
antibiotic could have an equally large effect as that from changing the type of antibiotic [203]. Our 
study shows that when comparing fitness landscapes across various environments, the magnitude 
of environmental change is crucial for the amount of change we observe in bacterial populations.  
One interpretation of the decrease of ruggedness as environments get more stressful is that 
there is a relaxed evolutionary constraint, where fitness landscapes have a smaller number of local 
maxima. Therefore, more genotypes can be connected in a path that leads to the highest fitness 
endpoint available. Meanwhile, the relaxed constraint also means that one genotype would be less 
committed in a path to any specific peak. A previous study has extensively analyzed the landscapes 
of a transcription factors from different eukaryotic species using their binding affinity [213]. The 
authors showed the number of peaks and the types of epistasis were directly related to the 
navigability of landscapes, which may have been an important mechanism to generate variation 
and innovation of transcriptional regulation [213]. Moreover, the magnitude of epistasis with any 
number of mutations generally is lower in a less rugged landscape, which is not surprising, since 
epistasis causes ruggedness.  
Although the pairwise epistasis often changes in sign, epistasis at higher-orders almost 
always only changes in magnitude. This could be explained by how genes or mutations are 
organized genetically or biochemically. In general, the order of action of genes in a regulatory 
hierarchy governs the phenotypic effect of epistatic mutations [214]. Disabling two genes in 
genetically compensatory pathways can lead to synthetic lethality [215], while disabling two genes 
in the same linear biochemical pathway can have a much more modest effect [214]. Weinreich et 
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al. assessed the influence of this principle by examining 16 published, biological fitness landscapes 
[216]. They found that on average the effects of epistasis declined with the order of epistasis. 
Another example is a study from Palmer et al. where seven mutations in the dihydrofolate 
reductase gene in E. coli that confer resistance to trimethoprim were examined [217]. They showed 
that adding a third-order interaction did not create more pathways or peaks than the number of 
distinct peaks generated by pairwise sign epistasis [217]. The significance and prevalence of higher 
order interactions have been controversial with some studies showing compelling results on 
increasingly frequent higher order interactions with increasing interacting components [218], 
while other studies show a pattern of diminishing return [219]. We suspect these differences 
probably arise from different biological systems or the mathematical frameworks used to quantify 
interactions.   
The change in sign of pairwise epistasis can have profound evolutionary consequences. For 
example, in the environment of LVX where ruggedness is high, topA is the fittest single mutant. 
The gene topA in E. coli encodes for topoisomerase I, which is responsible for relaxing negative 
supercoiling of the DNA by causing single-stranded DNA breaks [220]. The antibiotic LVX acts 
by inhibiting topoisomerase type II (also known as DNA gyrase) and type IV, and therefore impairs 
the replication, transcription, recombination, and repair of DNA [221]. Resistance to LVX or other 
fluoroquinolones typically involves mechanisms to alter the structure of the targeted 
topoisomerases so the antibiotics can no longer bind to their targets or the binding affinity is 
reduced [221]. Although topA is not a direct target, some studies show it could be the subject of 
selection for fluoroquinolone resistance [222]. The exact mechanism of resistance from non-
targeted genes is not fully understood [222]. It is possible that mutations in genes that control 
supercoiling, such as topA and fis, can impact the evolutionary flexibility of cell due to the overall 
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changes in chromosome structure [222]. This could explain the fitness advantage that we observe 
for topA mutant when CPR and LVX are added.  
When a secondary mutation is paired with topA, they tend to interact synergistically, where 
the combined fitness is smaller than expected. As a result, the double mutants could be removed 
from the population more efficiently because they are much less fit than expected with no 
epistasis. In the context of antibiotic resistance evolution, the synergistic epistasis at the specific 
antibiotic concentration would promote the specialization of topA mutant, while driving other 
genotypes extinct. This type of dose specialization aided by epistasis can be an important 
mechanism of resistance evolution.  
When the environment gets more stressful—that is, at higher antibiotic concentrations—
the fitness of topA mutant decreases to a similar level as the other mutations, and pairwise epistasis 
that involves topA switches signs, from negative to positive. Here the fitness of a double mutant is 
greater than expected based on the fitness effects of the two single mutants. This is therefore an 
antagonistic epistasis between two deleterious mutations, which is prevalent in our dataset and 
common in some studies with bacteria [223-225]. 
A previous study has suggested the mechanism for such antagonistic epistasis of 
deleterious mutations. Researchers used an error-prone DNA polymerase of Salmonella where 
deleterious mutations could accumulate randomly [226]. They found an increased expression of 
heat shock chaperones, namely DnaK and GroEL, in their evolved lineages, that have been shown 
to assist in the folding of proteins with damaged confirmation [227]. Experimentally-induced 
overproduction of GroEL further rescued the fitness decrease. For bacterial population that 
experience constant environmental fluctuations, it might be advantageous to maintain genetic 
variation where a genotype may be less fit in one environment but more fit in another [228].  
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For deleterious mutations, negative (synergistic) epistasis is proposed to be advantageous 
in purging those mutations [229-231], when the fitness reduction is greater with the combination 
of deleterious mutations than expected based on their individual effects. This is a critical premise 
for the mutational deterministic hypothesis which postulates that high recombination rates are 
maintained due to synergistic epistasis where deleterious mutations can be removed more 
efficiently [232]. From simpler genomes of RNA viruses to more complex multicellular eukaryotes, 
epistasis tends to transition from antagonistic to synergistic [225, 233]. In bacteria, E. coli was 
shown to exhibit roughly equal amounts of synergistic and antagonistic epistasis by measuring the 
individual and combined pairwise effects on fitness of mutations in recombinant genotypes [234]. 
Here we show that environmental differences can be a force that drives the change between 
synergistic epistasis that purges mutations and antagonistic epistasis that could help maintain 
genetic variation.  
Our work can help explain adaptation in a heterogeneous environment, by examining the 
changes in fitness landscapes across various environmental gradients. Since concentration 
gradients of antibiotics is likely ubiquitous from natural soil environment [235] to human tissues 
and organs [236]. Spatial heterogeneity has been proposed to play a role in the emergence and 
maintenance of genetic diversity and antibiotic resistance evolution [206, 237-245]. Our findings 
on the changes in fitness landscape topology and the underlying differences in ruggedness and 
epistasis interaction provide empirical evidence for a potential strategy for bacterial populations 
to combat environmental fluctuations or persist in a heterogeneous environment.  
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